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Bioﬁlms: Formation, Research Models, Potential Targets,
and Methods for Prevention and Treatment
Yajuan Su, Jaime T. Yrastorza, Mitchell Matis, Jenna Cusick, Siwei Zhao,
Guangshun Wang, and Jingwei Xie*
microorganisms existed only as planktonic
cells or ﬂoating cells.[1] J. William Costerton, a Canadian microbiologist, changed
that view in the late 1970s when he observed
microbial aggregates which were known as
bioﬁlms.[2] Bioﬁlms are often described as
microbial communities attached to material surfaces, formed by pathogens embedded in their own extracellular matrix (ECM)
composed of several types of biopolymers,
including extracellular polysaccharides, extracellular DNA, proteins, and lipids.[3] Microorganisms in the bioﬁlm account for
<10% of dry mass, while ECM can account
for >90%. The ECM forms the scaﬀold and
typical 3D structure of the bioﬁlm.[4] In addition, the multiple functions of extracellular polymer matrices, including adhesion,
intercellular aggregation, bioﬁlm cohesion,
water retention, barrier protection, and nutritional support, provide a wide range of advantages for bioﬁlm formation.[5]
Bioﬁlm formation goes through ﬁve steps.[6] i) Individual
plankton bacterial migrate and adhere to the surface. Under appropriate conditions, the attached bacteria start to form bioﬁlms
with a coating of a small amount of exopolymeric material. ii) Attached bacteria secrete extracellular polymeric substance (EPS)
and stick to the surface, resulting in a conglomeration of bacteria and matrix production. iii) Bioﬁlms fully develop by forming
microcolonies and water channel structures, and become more
layered. iv) Fully mature bioﬁlms reach their peak cell density
and function as 3D communities. v) Mature bioﬁlms release bacterial microcolonies from the primary community, seeding new
sites and spreading the infection. Such bioﬁlms make it diﬃcult
for antibiotics to penetrate the matrix and kill the hidden bacteria.

Due to the continuous rise in bioﬁlm-related infections, bioﬁlms seriously
threaten human health. The formation of bioﬁlms makes conventional
antibiotics ineﬀective and dampens immune clearance. Therefore, it is
important to understand the mechanisms of bioﬁlm formation and develop
novel strategies to treat bioﬁlms more eﬀectively. This review article begins
with an introduction to bioﬁlm formation in various clinical scenarios and
their corresponding therapy. Established bioﬁlm models used in research are
then summarized. The potential targets which may assist in the development
of new strategies for combating bioﬁlms are further discussed. The novel
technologies developed recently for the prevention and treatment of bioﬁlms
including antimicrobial surface coatings, physical removal of bioﬁlms,
development of new antimicrobial molecules, and delivery of antimicrobial
agents are subsequently presented. Finally, directions for future studies are
pointed out.

1. Introduction
1.1. Bioﬁlm Formation
In the past few decades, the paradigm of microbiology has
undergone a revolutionary shift. It was initially thought that
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1.2. Bioﬁlms in Chronic Wounds
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Chronic wounds often refer to wounds that fail to heal within a
normal timeframe (usually within 1.5 months). Chronic wounds
include a diverse array of diﬀerent clinical scenarios such as
surgical wounds, venous leg ulcers, diabetic foot ulcers (DFUs),
and pressure ulcers.[7] Due to the inherent pathophysiology of
these wounds and the polymicrobial nature of the wound environment, chronic wounds often do not heal.[8] Chronic wounds
are an important and increasingly serious problem in today’s
medical care.[9] In the U.S. 2% of the population potentially develop chronic wounds.[10] The estimated cost for management of
chronic wounds surpasses $50 billion annually.[11]
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The unique micronutrients, wound surface, and exudate produced by the wound provides an ideal environment that supports
three diﬀerent phenotypic states for the growth of microorganisms: free-ﬂoating (planktonic), attachment (sessile), and quasisessile (ﬁrst from the biological membrane separation of microbial aggregates or ﬂocculation body).[12] Sessile bacteria on the
surface dynamically divide multiple times and form aggregate,
forming microcolonies, which then merge to create dynamic entities called bioﬁlms.[13] Interestingly, the growth of microorganisms in bioﬁlms follows the principle of “group selection” rather
than “individual selection”.[14] This seems critical for the managing infections associated with bioﬁlms.[15]
In 2004, bioﬁlms were conceptually reported to be the root
cause of nonunion and long-term infections seen in the majority of chronic wounds.[16] In 2008, James and his colleagues
strengthened this hypothesis by showing that 60% of chronic
wounds contained bioﬁlms.[7] Lately, the role of bioﬁlms in delaying chronic wound healing and increasing risk of infection has
been further demonstrated by many studies.[17] In 2012, Römling
and Balsalobre showed that more than 80% of surgical site infections (SSIs) develop bioﬁlms.[18] However, the guidelines provided by the Centers for Disease Control and Prevention (CDC)’s
SSIs prevention advisory committee do not mention bioﬁlms.[19]
Bioﬁlms are diﬃcult for the host’s immune system to defeat. The
immune response to bioﬁlms includes the stimulation and recruitment of polymorphonucleocytes and white blood cells, resulting in chronic inﬂammation that delays wound healing.[20]
Studies have shown the importance of bioﬁlms in the persistence
of wound infections, and the polymicrobial properties of bioﬁlms
are believed to be one of the chief factors that cause the recurrence of wound infections.[21]
Around 15–25% of diabetic patients have DFUs in their
lifetime.[22] Infected DFUs are one of the most serious complications and potentially lead to lower limb amputations.[23] Infection, poor healing, and ischemia are characteristics of DFUs.[24]
In fact, 80% of patients with diabetes develop bioﬁlm-infected
foot ulcers before lower limb amputation.[25] Infected DFUs are
also associated with a higher mortality rate within 18 months.
The interface between the host and microbes is critical in the
development of DFUs.[26] In DFUs, diﬀerent bacteria are assembled into pathogroups with similar functions, which cause
pathogenic and symbiotic bacteria to sustain chronic infections
in bioﬁlms.[27] Such polymicrobial bioﬁlms have been seen in
both preclinical animal models and in patients with DFUs. They
represent a major cause of delayed healing. The photographs
shown in Figure 1A illustrate the diﬀerent clinical perspectives
of DFU infection, including four stages: contamination, colonization, critical colonization of localized infection, and severe
spreading infection/chronicization.[28]
In the 2010s, much clinical research demonstrated the presence of bioﬁlms in chronic wounds. Neut et al. reported two case
studies about nonhealing ulcers in people who have diabetes mellitus in 2011.[29] Evidence of bioﬁlms was shown in these patients’
DFUs using laser scanning confocal microscopy imaging. Malik
et al. found bioﬁlms in 67.9% of 162 patients with diabetic foot
infection (DFI).[30] In addition, Oates et al. visualized the bioﬁlms
in the tissues debrided from chronic wounds in diabetic patients
using ﬂuorescence in situ hybridization and scanning electron
microscopy (SEM).[31]
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It is believed that a single bacterial species do not cause
bioﬁlm formation during infection, especially in chronic wounds
as microbes in bioﬁlms are often polymicrobial.[32] The interactions between microorganisms are complicated and signiﬁcantly contribute to the pathogenesis of bacterial bioﬁlmassociated infections.[33] These interactions can be antagonistic or cooperative. They often include rivalry for nutrients or
collaborative mechanisms aiding their reciprocal growth in
particular environments.[34] The close-contact between bacteria in bioﬁlms enhances molecular communications between
bacteria.[34,35] Bacteria communicate by diﬀusing molecules,
such as the homoserine lactones or quinolones produced by
Gram-negative bacteria, or the short peptides produced by Grampositive cocci.[36] In addition, this proximity allows horizontal gene transfer, facilitating resistance to antimicrobial agents
and improving the survival of the bioﬁlm. Mottola et al. examined 53 clinically derived Staphylococcus samples from DFU patients and found that bioﬁlms are 10–1000 times more resistant to antibiotics than planktonic cells.[37] In their studies, only
two antibiotics including gentamicin and ceftaroline can destroy
bioﬁlms among the 10 antibiotics investigated. Bacterial bioﬁlms
are reported to oﬀer high resistance to heavy metals and ultraviolet light as well. Other than bacteria, fungal species, in
particular candida, were also found in bioﬁlm-containing DFU
specimens.[37]

1.3. Bioﬁlms in Burns
Burns extensively damage soft tissue, and, depending on the
severity of the burn, may result in deep wounds and/or death.[38]
Medical treatment of burns has always been a diﬃcult problem, which has given rise to many diﬀerent methods to treat
the damaged area.[39] The presence of bioﬁlms delays burn
wound healing as it causes a continuous, low-grade, inﬂammation, hindering the formation of granulation tissue and reepithelialization.[40] One method for avoidance and management
of burn infections is the administration of antimicrobial agents
to kill bacteria.[41]
One of the biggest challenges facing burn clinics is the complication of bacterial infections within burn wounds, which can lead
to more serious disease states, including sepsis.[42] The lack of
new antimicrobials, particularly those eﬀective against bioﬁlms,
further exacerbates the challenge of treating drug-resistant microorganisms in burn wound infections.[43] In the immediate
hours and days following a burn, Gram-positive Staphylococci colonize the surface of the wound, as they are members of normal
skin ﬂora and are resistant to thermal damage.[44] Other bacterial
and fungal species (e.g., Pseudomonas aeruginosa (P. aeruginosa))
re-colonize the burn wound surface usually within one week after the burn. Contamination of burn wounds by P. aeruginosa
could cause invasion and sepsis, which may be fatal. Figure 1B
shows representative images illustrating the characterization of
bioﬁlms in full-thickness burn wounds.[45] Figure 1B (I) shows
a formed bioﬁlm on an ulcerated burn wound. Wound dressing
remains are noticed in the top left. Figure 1B (II) shows a transmission electron microscopy (TEM) image of the mixed bacterial
bioﬁlm made up of rods and cocci, part of which are degenerated
indicated by arrows. Figure 1B (III) shows an SEM image of the
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Figure 1. Representative bacterial bioﬁlms within the clinical setting. A) The process of DFU wound infection, chronicization, and bioﬁlm colonization.
Reproduced with permission.[28] Copyright 2019, MDPI. B) Representative images of bioﬁlms on the full-thickness burn wounds. I): Large collections
of gram-positive cocci form a bioﬁlm on the surface of an ulcerated burn wound. Wound dressing remnants are present on the top left. II): Low power
transmission electron micrograph of a mixed bacterial bioﬁlm consisting of rods and cocci, some of which are degenerated (arrows). III): Scanning
electron micrograph of the edge of an escharotomy site. The burn surface can be observed on the top right. A large collection of mixed bacteria with the
typical appearance of a bioﬁlm can be seen below the surface within dermal collagen. Reproduced with permission.[45] Copyright 2010, Elsevier. C) In
vivo evidence suggesting H. pylori bioﬁlm formation in the gastric glands of humans. I): Large aggregates of H. pylori colonizing the surface of gastric
glands; II): H. pylori aggregates colonizing the neck of gastric glands, with proliferative cells; III) colonies of H. pylori deep in the gland, in the vicinity of
stem cells. H. pylori stained in green, actin stained in red and DNA nucleus stained in blue. Reproduced with permission.[58] Copyright 2019, Frontiers
Media S.A. D) Dental plaque architecture: The EPS matrix, spatial organization, and polymicrobial composition. I): Plaque bioﬁlm from a caries-active
subject: microscopic image (inset) of plaque-bioﬁlm showing a selected area containing bacterial cells (highlighted in orange) enmeshed in EPS (in
dark blue); the image was pseudo-colored using Adobe Photoshop software for visualization purposes. II): Bacterial clusters (green) surrounded by
EPS matrix (red) detected in mature mixed-species oral bioﬁlms formed in sucrose. III): Spatial organization of human dental plaque showing multiple
clusters of varying sizes containing diﬀerent microbial species. Reproduced with permission.[71] Copyright 2018, Elsevier. E) I): A catheter was removed
surgically that had been indwelling suprapubically for 6 months. Crystalline material completely covered the eyehole and balloon of the hydrogel-coated
latex catheter. II): A cross-section of a silicone catheter that had been indwelling for 8 weeks. The image shows that the central lumen was occluded
by crystalline bioﬁlm. III): A longitudinal section of a silver-hydrogel-coated latex catheter that became blocked after 11 days in situ. Reproduced with
permission.[86] Copyright 2008, Springer Nature.
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edge of an escharotomy site. The burn surface is displayed in the
top right. Massive accumulation of varied bacteria with the representative feature of a bioﬁlm was observed beneath the surface
within the dermis. The existence of bioﬁlm in the burn wound
poses challenges to managing burns. The best practice entails
early excision and coverage of the burn wound to prevent the colonization of multiple bacteria.

pathogen, conﬁrming that the in vivo microbial aggregates were
formed exclusively by H. pylori. The mechanism of the interactions between the bioﬁlm community and the gastric mucosa in
diﬀerent niches of the gland could be useful for understanding
the cause of serious diseases, such as gastric cancer and peptic
ulcer. In particular, large aggregates of H. pylori growing in intimate contact with stem cells could generate potential damage to
these cells due to the direct interaction with the bacteria.

1.4. Bioﬁlms in Gastrointestinal (GI) Tract
1.5. Bioﬁlms in Oral Cavity
The human GI tract extends from the esophagus to the rectum
and includes the stomach, small intestine, and large intestine
(colon). The GI tract contains a variety of microhabitats that are
variously colonized by microorganisms based on the conditions
of the microhabitat.[46] Colonization gradients exist in the gastrointestinal tract, ranging from the scarcely populated esophagus and stomach to the densely colonized colon, where the luminal contents can accommodate as many as 10 12 culturable
bacteria/g.[47]
Many studies have shown the presence of both inﬂammation and microbial bioﬁlms within the GI system.[48,49] The
GI diseases associated with bioﬁlms that satisfy these conditions include Helicobacter pylori (H. pylori) infections, Barrett’s esophagus (BE), inﬂammatory bowel disease (IBD) (e.g.,
Crohn’s disease and ulcerative colitis (UC)), and nasogastric
(NG)/percutaneous endoscopic gastrostomy (PEG) tubes.[50] The
cause-and-eﬀect relationship between local H. pylori bioﬁlms and
persistence in the host has been reported.[51] H. pylori bioﬁlms
can be visualized directly in the gastric mucosa which are resistant to antimicrobial agents, making treatment diﬃcult.[52] Another GI disease, BE, is associated with localized nitrate reduction due to the bioﬁlms of Campylobacter and Veillonellas, which
could lead to metaplastic changes in esophageal squamous epithelial cells. Although important, studying a causal link between
these bacteria and progression to BE has proved diﬃcult.[53] The
microbiome related to IBD and the positive outcome of antibiotic therapy on these diseases have been described.[54] However,
as with diseases caused by other bioﬁlms, patients may endure a
“rebound eﬀect” after the termination of antibiotic treatment because the bacteria not fully cleared by antimicrobial agents could
regrow in the GI tract, likely resuming IBD symptoms.[55] Indwelling medical devices associated with bioﬁlms have been thoroughly described such as NG tubes and PEG tubes in neonatal
and elderly patients. The microbial species associated with this
phenomenon include Enterobacteriaceae, S. aureus, lactobacilli,
and Candida spp., all of which have shown an increased resistance to elimination by antimicrobial agents in the form of
bioﬁlms as opposed to individual cells.[56,57] Therefore, due to the
many diﬀerent infections on these indwelling devices, their replacement becomes the last resort although undesired. Figure 1C
shows the in vivo evidence of H. pylori bioﬁlm formation in the
gastric glands of humans.[58] Figure 1C (I) shows colonized H.
pylori on the surface of gastric glands. Figure 1C (II) shows colonized H. pylori aggregates on the neck of gastric glands, with
proliferating cells, and Figure 1C (III) shows colonized H. pylori
deep in the gland, close to stem cells. H. pylori, actin, and nuclear DNA were stained in green, red, and blue, respectively. In
this study, H. pylori was stained with antibodies speciﬁc to the
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Due to the warmth, high humidity, and rich nutrients,
oral cavity oﬀers a perfect environment for the growth of
microorganisms.[59] The complicated interplay between microorganisms, host, and diet can lead to the emergence of pathogenic
oral bioﬁlms.[60] Oral bioﬁlms can form on the surface of teeth
or other dental surfaces and have shown to be an important virulence factor in a lot of oral infections.[61]
Bacteria can colonize on two types of surfaces within the oral
cavity, including the hard surface of the teeth and the soft tissue of the oral mucosa. The teeth, tongue, gingival groove, hard
and soft palates, cheeks, and tonsils all have favorable conditions
for the growth of microbial colonies.[62] These microbial aggregates are in the form of bioﬁlms distinguished by their composition, coverage or matrix combination, and regulatory membranes covering the surfaces on which they are arranged.[63] Due
to changes in basic environmental conditions, the arrangement
of resident oral microbiomes on diverse surfaces shows regional
diﬀerences. Each niche provides a diﬀerent optimal state and nutritional requirements for its hosted microbes. In this sense, the
jaw, tongue, and hard and soft palates contain distinct bacterial
components.[64] In addition, the oral microbiome is highly dynamic due to the frequent contact between the oral cavity and
the external environment.[65] As a result, the oral microbiota has
developed the ability to deal with diﬃculties that no other microbiome has encountered. The growth and activity of bacteria in the
mouth are aﬀected by feeding and preventing disease.[66] In addition, microbial ecosystems are inﬂuenced by hygiene practices.
However, oral microbial colonies with less sensitivity to disturbances undergo alterations related to health, diet, and age, along
with steady variations in pH, redox potential, salinity, climatic
conditions, and salivary water activity.[67] Oral cavity bacteria are
divided into 13 independent phyla, including Acidobacteria, Actinobacteria, Bacteroidetes, Chloroﬂexi, Cyanobacteria, Deinococcus,
Firmicutes, Fusobacteria, Proteobacteria, Spirochaetes, Synergistes,
SR1, and TM7.[68]
Bacterial bioﬁlms are the primary cause of dental diseases.
Dental caries are typically caused by bioﬁlms, resulting in mineralized tooth tissue loss.[69] Microorganisms in the mouth are
necessary to cause caries, but that is not enough, because the
formation of caries bioﬁlm depends on the diet of the host.[70]
A sugar-rich diet boosts the aggregation of EPS and simulates
the agglomeration of acid-producing/resistant microbiota, which
is evidenced by microscopic images of plaque bioﬁlms collected
from the active site of caries that show bacteria within a rich
EPS. (Figure 1D).[71] Figure 1D (I) shows the plaque bioﬁlm from
a caries-active subject, and the plaque-bioﬁlm containing bacterial cells enmeshed in EPS. Figure 1D (II) shows the bacterial
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aggregates embedded in EPS identiﬁed in hybrid-species oral
bioﬁlms established in sucrose. Figure 1D (III) shows a human
dental plaque with many aggregates of various sizes consisting
of diverse microbial species. Streptococcus mutans (S. mutans) is
a major bacterial strain associated with dental caries. Much research, including clinical, epidemiological, and animal studies,
has shown that S. mutans is closely related to the disease, particularly in early childhood caries.[72] One of the major adaptations
that makes S. mutans an eﬀective opportunistic pathogen in the
oral microbiome is its special ability to use many diﬀerent carbohydrates to produce EPS and acids, which allows it to easily assemble into bioﬁlms. This ability includes mechanisms of stress
resistance and bacteria ability. S. mutans obviously does not cause
caries alone, its dynamic and collaborative interactions with multiple other organisms allow for the assembly of caries-producing
bioﬁlms.[73]

1.6. Bioﬁlms On/Within Medical Implants
Bioﬁlms are commonly found on indwelling medical devices including catheters, heart valves, pacemakers, artiﬁcial joints, voice
prostheses, and contact lenses.[74] Bioﬁlms may be formed out of
a single or multiple microbial species, relying on the device and
the duration it has been implanted for.[75]
There are two kinds of contact lenses, soft and hard which are
classiﬁed based on building materials, disposal frequency, wear
schedule, and design. Microbes can attach themselves to both
types of lenses.[76] The main types of microbes found on contact lenses include E. coli, P. aeruginosa, S. aureus, S. epidermidis,
and species of Candida, Serratia, and Proteus.[77] The extent of attachment to the lens is subject to the hydration status, substrate
characteristics, electrolyte contents, bacterial species, and polymer types.[78] Bioﬁlms have been found by SEM on contact lenses
of patients with diagnosis of keratitis due to the P. aeruginosa contamination. Contact lenses stored in cases may have more frequent bioﬁlm growth. Lens storage cases have thus been believed
to be a common source of contamination.[79]
Bioﬁlms are commonly found on central venous catheters. The
kind of bioﬁlm, the location of the growth, and how pervasive
the bioﬁlm are all depend on the duration of the catheter insertion. For example, catheters that have been indwelling for fewer
than ten days tend to form bioﬁlms on the outer surface of the
catheter, meanwhile long-term (30 days) catheters form more
bioﬁlms in the lumen.[80] Additionally, microbial growth could
be inﬂuenced by the kind of ﬂuid introduced through the central venous catheter. For instance, Gram-positive bacteria (e.g., S.
epidermidis and S. aureus) grow poorly in intravenous ﬂuids, but
gram-negative aquatic bacteria (e.g., P. aeruginosa, Enterobacter,
and Klebsiella) thrive in such ﬂuids.[81]
Microbes that have adhered to heart valves and their surrounding tissues often generate bioﬁlms, which produces a condition
called prosthetic valve endocarditis. This kind of infection is most
often caused by S. aureus, S. epidermidis, Streptococcus species, Enterococcus, gram-negative Bacillus, and Candida spp.[82] These microorganisms may derive from the endogenous ﬂora on the skin
or from other indwelling devices like central venous catheters or
dental implants. Surgical damage during prosthetic valve implantation may also cause an accumulation of platelets and ﬁbrin at
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suture sites, which provides an ideal milieu for bacterial colonization and subsequent bioﬁlm formation.[83]
Most commonly, urinary catheters are constructed of silicon
or latex, and are often employed during surgery to evaluate urine
production.[84] The catheter is inserted through the urethra and
into the bladder. This kind of catheterization may be open or
closed to the outside environment. In a catheter system open
to the outside, urine is discharged at an open collection center,
likely leading to higher chances of contamination and urinary
tract infections (UTIs) in just a few days. In closed ductal systems, urine accumulates in plastic bags, thus minimizing the
opportunities for contamination and resulting in lower rates of
UTIs. Microbial contamination and bioﬁlm formation on urinary
catheters are most commonly from E. coli, E. faecalis, S. epidermidis, P. aeruginosa, and other bacteria.[85] Figure 1E (I) shows
an indwelling catheter after use for 6 months. After surgical removal, crystalline materials fully covered the eyehole and balloon
of the latex catheter coated with hydrogel. Figure 1E (II) shows a
cross-section of an indwelling silicone catheter after application
for 8 weeks, indicating the central lumen was blocked by crystalline bioﬁlms. Figure 1E (III) shows a longitudinal section of a
silver-hydrogel-coated latex catheter that was clogged after application for 11 days.[86] These bioﬁlms formed on the outer surface of the catheter around the balloon and catheter tip could
cause trauma to the bladder and urethral epithelia. When the
retained balloon is deﬂated, crystalline debris from the bioﬁlms
may fall oﬀ into the bladder and trigger stone formation.[86] However, the major complication is obstruction of urine ﬂow through
the catheter likely due to the accumulation of crystalline material
on the luminal surface. As a result, urine leakage often occurs
along the outside of the catheter and patients would have urinary
incontinence, leading to an increased need for care. In addition,
the blockage of the catheter could cause retention of urine in the
bladder and vesicoureteral reﬂux of infected urine. If the blockage is not detected and the catheter is not replaced, patients would
suﬀer episodes of pyelonephritis and septicemia.

1.7. Clinical Detection of Bioﬁlms
There are two main types of bioﬁlm infections. One is related
to bioﬁlms in tissues (e.g., chronic wound infections, lung infection, and gastric H. pylori infection), and the other is medical
devices associated bioﬁlm infections (e.g., intravenous catheters,
orthopedic alloplastic devices, endotracheal tubes, indwelling urinary catheters, and tissue ﬁllers).[87] Accurate detection or diagnosis of these bioﬁlm infections is critical for their successful
treatment (e.g., selection of appropriate antibiotic therapy). Here,
we highlight the detection of bioﬁlms in several important clinical scenarios.
For patients with chronic wound infections, it is important
to detect the location of bioﬁlms and the pathogen types. It is
recommended to collect the biopsy tissue from the postdebridement wound bed for chronic wounds with suspected bioﬁlm infections. Three major assays have been used for the bioﬁlm diagnosis including morphology assay (e.g., tissue biopsy for histology and SEM and confocal laser scanning microscopy (CLSM)
for detecting the location of bioﬁlms), microbiology assay (e.g.,
bacterial culture for detecting the bacterial type) and molecu-
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lar assay (e.g., 16S rRNA PCR for detecting the pathogen type).
The advantages and drawbacks of each assay were listed in a recent excellent review article.[87] For the gastric H. pylori infection,
two major methods are currently used for its detection. One is
an invasive test, which involves the use of endoscopy to observe
mucosa and sample biopsies in multiple locations followed by
histopathological analysis (a gold standard with 95% of sensitivity and 98% of speciﬁcity). Rapid urease test and culture and organism genotyping could be used to assist the detection as well.
The other one involves noninvasive tests such as urea breath testing, stool antigen assay, and tests on plasma, blood, saliva, and
urine. It is worth mentioning that GastroPanel representing a
new-generation test evaluates antibodies and pepsinogen I plus
and pepsinogen II and gastrin-17 in the plasma simultaneously
with 94–95% of accuracy.[88] For lung infection, examining sputum sample microscopically and culturing expectorants remain
the major method for diagnosis because of its simplicity, quickness, and low cost.[89] However, sputum examination may not be
able to detect infections due to false negative results and contamination issues, more invasive methods can be used for sampling
such as pulmonary endoscopy (e.g., bronchoscopy), transthoracic
needle aspiration, and surgical biopsy of lung parenchyma. Similarly, culture, histology, nucleic acid test, and antigen testing
allow the detection of suspected pathogens. In addition, many
microbiologic assays (e.g., serum, nasopharyngeal swab, throat
swab, urine, sputum, and body ﬂuid) are available for diagnosis
of lower respiratory tract infection.[90]
Patients with suspected infections associated with orthopedic implants, synovial ﬂuid is collected for pathogen detection
initially.[87] Then, debridement is suggested if the aspirate with
white blood cell count is larger than 25 000 per mm3 .[91] Three
to six biopsies (less than 1 cm3 ) from peri-implant tissue should
be acquired based on the clinical practice guidelines.[92] In addition, sonication of the explanted orthopedic implant or parts
can assist the release of bioﬁlms. The same pathogen appears
in more than two culture specimens, conﬁrming periprosthetic
joint infection.[93] SEM could also be used to directly visualize the
bioﬁlms on the surface of implants. For the suspected catheterassociated infection, qualitative and quantitative blood cultures
from vascular catheter and peripheral blood should be performed
for diagnosis if the catheter is still in place.[94,95] For the removed
catheter, the tip should be tested for a quantitative culture (threshold larger than 103 CFU/mL) after sonication or vortex.[96] Alternatively, a semiquantitative culture (threshold larger than 15
CFU) should be performed by rolling the catheter tip on an agar
plate.[97] It seems that most of the current methods for clinical detection of bioﬁlm infections necessitate acquiring biopsies in an invasive way. Further studies are required to improve
the detection of bioﬁlm infections in diﬀerent clinical scenarios such as new non-invasive approaches for detecting bioﬁlms
in situ.[98]

1.8. Clinical Therapy
1.8.1. Debridement
Debridement is widely used in clinics to treat diﬀerent bioﬁlms,
which is performed by making use of mechanical destruction
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and/or chemicals.[99] Debridement methods vary from sharp,
specialized surgical debridement, to gentle mechanical debridement using curettes, fabric pads, douches, or ultrasound, to autolysis debridement using moisturizing dressings. Physical debridement is obviously the simplest and most eﬀective method
to eliminate bioﬁlms, nonviable tissue, and foreign debris.
While physicians have long known that debridement of carrion
promotes healing, debridement can also remove bacteria that
have colonized necrotic wounds and those growing in wound
bioﬁlms.[100] Water irrigation techniques have been developed
and are used for the removal of pathogen bioﬁlms (e.g., SSIs,
dental bioﬁlms).[101] High-speed imaging has provided important
insights into the ﬂuid-bioﬁlm surface interactions, revealing that
bioﬁlms liquidize and spread across the entire surface despite the
removal of a signiﬁcant amount of bioﬁlm from the region.[102]
The ﬂuidization of bioﬁlms contributes to the persistence of bacteria on the surface after water-based removal and may result in
the poor eﬃcacy of treatment by rinsing and debridement for
periprosthetic infections. Water-based jets remain useful because
antimicrobial therapeutics can be incorporated, thus the ﬂuid can
double as both a delivery device and a debridement device.[103]
Solutions or gels having preservatives (e.g., sodium hypochlorite or hypochlorite) are normally used for enzymatic/chemical
debridement.[104] Regardless of the removal method, clinical experience has shown that bioﬁlms reform quickly within a day.
Therefore, regular debridement is one of the key methods to removing bioﬁlms. In addition, while slough is adjacent to underlying healthy host tissues, bioﬁlms are often located on the very
surface and thus likely respond better to milder debridement
approaches like fabric pads, curettage, or chemical rinses.[105]
While debridement is intended to get rid of deactivated tissue
and “repel” the bioﬁlm to avoid reforming, it is only eﬀective with
the subsequent application of appropriate antibiotics and wound
management products.[106]

1.8.2. Topical Antimicrobial Therapy
Although there are some advances in anti-bioﬁlm therapies, especially for indwelling devices, the most common strategies are
topical antimicrobial therapy. However, antibiotic resistance is
on the rise worldwide and new treatments are urgently needed
to address this challenge in healthcare.[107] A large number of
antimicrobials currently available (e.g., antibiotics, silver-based
products, iodine) could be confusing to healthcare professionals.
Antibiotics should be administered carefully and with discrimination, only when infection is suspected clinically or conﬁrmed
by testing.[108] Debridement eliminates part of the protective bacteria in bioﬁlms provided by EPS, making the rest bacteria to increase their metabolic activity to rebuild. In this scenario, antibiotics originally developed to kill bacteria in the planktonic state
and topical antimicrobials including silver, iodine, and polyhexamethylene biguanide become highly eﬃcacious.[109]
The delivery system of an antimicrobial agent is just as critical as the speciﬁcally selected agent. The delivery system must
interact optimally with the wound microenvironment.[110] For instance, for wounds with bioﬁlm exudation, a highly absorbable
antimicrobial dressing should be applied following debridement.
The application of sterile gauze or mesh is not appropriate be-
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cause of insuﬃcient exudate absorption capabilities. However,
most topical antimicrobial products currently available have limited eﬃcacy against bioﬁlms.[111] A careful combination of debridement, antimicrobial agents, and wound care products is the
most eﬀective strategy for the treatment of bioﬁlms-containing
wounds.
Silver sulfadiazine remains the most popular drug with an excellent activity proﬁle, low toxicity, and ease of use with marginal
pain. Silver sulfadiazine is believed to act by inhibiting DNA
replication and modifying cell membranes and walls. It is effective in killing both gram-positive and gram-negative bacteria;
however, resistance has been revealed sporadically.[112] Silver sulfadiazine is one of the therapies used to prevent and treat infections in second- and third-degree burns. However, continued
use of this treatment in large burns (> 50qc, total surface area,
TBSA) fails.[113] If infection is present or suspected, appropriate
systemic antibiotic agents may be required. Cerium nitrate may
be useful alongside silver sulfadiazine. Cerium nitrate has shown
in vitro antibacterial activity and changes cell-mediated immunosuppression after burns.[114] Adding cerium nitrate to silver sulfadiazine may improve antimicrobial activity against gram-positive
and gram-negative organisms and fungi. However, the use of
cerium nitrate with silver sulfadiazine in clinics shows the same
eﬃcacy as silver sulfadiazine itself. Such a combination of drugs
results in adherent eschar with satisfactory wound coverage before performing tangential excision.[115]
Povidone iodine ointment oﬀers an eﬀective combinatorial
therapy combining the antimicrobial property with the moist
environment required for wound healing. Even with the widespectrum antibacterial activity, the application of povidoneiodine-based products for burn treatment remains debatable
due to their toxicity to cells and delayed wound epithelial
regeneration.[116] Furthermore, povidone iodine ointments need
to be applied four times per day to exhibit the largest antibacterial eﬃcacy, which is a major disadvantage of this therapy when
compared with other local antimicrobial drugs.[117]
At the same time, many other antimicrobial agents are also applied for topical antimicrobial therapy. Dakin’s solution (0.025%
sodium hypochlorite) is widely used in a variety of refractory
wound types and is advised for burn wound management. It
has a wide spectrum of bacterial killing and is eﬀective against
the clinical setting of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and other
antibiotic-resistant bacteria.[118] Although norﬂoxacin along with
its silver salts has been formulated as topical creams due to its
broad-spectrum antimicrobial action, they require further investigations for the treatment of burns.[119] MRSA strains are increasingly common as hospital pathogens, especially in burn
wounds. Mupirocin has shown good eﬃcacy in combating MRSA
infections in vitro and in vivo. But there is a need to determine its safety and eﬀectiveness in the management of burns
greater than 20% TBSA. In addition, intranasal use of mupirocin
ointment seems to minimize the chance of MSRA-associated
infections.[120] Because of the emergence of gentamicin-resistant
bacteria, gentamicin cream should only be used for the management of gentamicin-susceptible P. aeruginosa infected wounds
and patients who show allergy to sulfonamides.[121] Many clinical
uses of bacitracin are for the prevention of gram-positive bacterial
infection in open spaces and the incorporation of neomycin and
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polymyxin B extends this antimicrobial eﬀect to Gram-negative
bacteria.[122]

2. Bioﬁlm Models for Research
2.1. In Vitro Bioﬁlm Models
In vitro models are very important to the understanding of
bioﬁlms. These models can be classiﬁed as static or dynamic
models according to the renewal of growth media and nutrients.
The nutrient supply for static models is limited as the medium
is not usually changed throughout the bioﬁlm growth phase in a
microplate. They are commonly used to assess bioﬁlm formation
and biomass accumulation. These models are cheap, simple, and
repeatable. Therefore, they are widely used to evaluate bioﬁlm
growth dynamics and activity of anti-bioﬁlm compounds.[123] Dynamic models, on the other hand, create an environment more
similar to natural conditions for bioﬁlm growth because there is
a constant nutrient supply throughout the process. With the renewal of the culture medium and the removal of metabolites, it
is possible to analyze the growth dynamics of bioﬁlms over an
extended period of time.[124] In addition, more sophisticated systems facilitating ﬂow displacement can be used to generate shear
forces and mass transfer, thus creating environmental conditions
similar to the in vivo environment.[125] Currently, several commercially available static models are available to study in vitro
bioﬁlms. Microtitration-based systems using 12, 24, or 96-well
plates are the most commonly used in vitro models. In these
models, cultured bioﬁlms are grown on the bottom and sides
of the microtitration plate or placed on a given surface within
the plate wells. These microplates provide a convenient and efﬁcient method for comparing the bioﬁlm-forming ability of bacterial mutants[126] or antibioﬁlm eﬃcacy of multiple antimicrobial compounds or combined eﬀects between them.[127,128] In addition, this method also enables multiple approaches to quantify bioﬁlms by diﬀerent staining methods (e.g., total biomass
by using crystal violet and live cells by using 2,3-Bis-(2-Methoxy4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT) to
get a more complete picture.[128] It appears that biomasses are reduced more rapidly than live bacteria in the bioﬁlm, depicting a
picture that the bioﬁlms matrix is ﬁrst disrupted followed by the
killing of bacteria hidden within bioﬁlms.
To examine the bioﬁlm formation on medical devices, Sanz
et al. developed in vitro bioﬁlm models by growing six bacterial
strains on titanium implants for diﬀerent durations (e.g., 12, 24,
48, 72, 96, and 120 h) (Figure 2).[129] Figure 2A shows a photograph of a methacrylate stent, 10 mm wide by 7 mm high, with
internal boreholes 2.7 mm in diameter and 5 mm deep, used to
ﬁx and support the implant, displaying the coronal third of the
implant. Figure 2B shows CLSM images of the entire dental implant obtained at 12 (I), 24 (II), 48 (III), 72 (IV), 96 (V), and 120
(VI) h in bioﬁlm culture using LIVE/DEAD BacLight kit. Live bacteria, dead bacteria, and implant surfaces can be distinguished
very clearly. Figure 2C shows SEM images of bioﬁlm growth on
the entire dental implant from 48 to 120 h. Image I shows a complex morphological bioﬁlm after incubation for 48 h, in which
Fusobacterium nucleatum forms a network with adherent bacterial
microcolonies. In images II and III, bacteria and extensive channels were observed at 72 and 96 h in the anticipated large masses.
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Figure 2. A representative in vitro bioﬁlm model. A) Photograph showing a methacrylate stent with 10 mm wide and 7 mm high and an internal drilling
with a diameter of 2.7 and 5 mm deep to support the implants in a ﬁxed position allowing the exposure of the coronal third of the implant surface. B)
CLSM Images obtained at 12 (I), 24 (II), 48 (III), 72 (IV), 96 (V), and 120 (VI) h of incubation of bioﬁlms over whole dental implants which were stained
using LIVE/DEAD BacLight Kit with live bacteria in green, dead bacteria in red, and implant surface in blue. C) SEM images showed bioﬁlm growth from
48 to 120 h over whole dental implants. I): Bioﬁlms after 48 h of incubation, with a complex morphology, in which Fusobacterium nucleatum formed
networks with the adhered microcolonies of bacteria. II,III): Bioﬁlms after 72 and 96 h of incubation, indicating the bacteria were in the expected larger
stacks (growing masses of bacterial cells) and presence of broad channels (green arrow) and the cell mass and ECM surrounding bacteria in the bioﬁlm
(white arrows). IV): The bioﬁlms after incubation from 72 to 120 h did not change in architecture. Reproduced with permission.[129,130] Copyright 2019,
Wiley-VCH.

The ECM (white arrow) surrounding bacteria in cell clusters and
bioﬁlms could be observed. Between72 and 120 h, the structure
of bioﬁlm remained the same, as shown in image IV. In general,
the result showed the bacteria colonies were formed on implants
rapidly, and bioﬁlms matured by 96 h and displayed various ratios between live and dead cells determined by their location. Live
bacteria were concentrated at the peaks of the threads. There is
a ﬂuctuation over time in terms of the densities of every colony
with maximum values reached at 96 h.

2.2. Ex Vivo Bioﬁlm Models
Several methods have been used to assess the infectious processes associated with bioﬁlm formation. The development of
ex vivo bioﬁlm models has bridged in vitro models and animal
models. In vitro models are not considered reliable due to the absence of signiﬁcant host-related biological factors. Animal models are often costly. Ex vivo models were proposed to bring exper-
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imental conditions closer to those observed in the host, once in
vitro methods can be modiﬁed to simulate situations that happen in vivo.[130] An important advantage of using ex vivo models is the possibility of reducing the number of animals used
in research, which reduces the cost of maintaining experimental animals while respecting animal welfare. It is therefore important to stress that these models should prioritize the use of
by-products from abattoirs to ensure optimum use of animals
for human consumption. However, ex vivo models aren’t without their signiﬁcant disadvantages. They lack the interaction of
the host immune system with bioﬁlms, and may lack competing
microbiota present at diﬀerent anatomical sites, and the insuﬃcient ﬂuid ﬂow observed in in vivo studies.[131]
The characteristics of an ideal ex vivo bioﬁlm model should
include: 1) the use of by-products from animal slaughter or
surgery (human or animal), which reduces research costs and
minimizes the use of healthy live animals; 2) easy control of
microbial growth (disinfection or sterilization) to reduce microbial competition and allow microbial growth for research; 3) easy

2203291 (8 of 36)

© 2022 The Authors. Advanced Science published by Wiley-VCH GmbH

www.advancedsciencenews.com

www.advancedscience.com

maintenance of tissue viability, which will reduce the cost of enrichment media or other reagents; and 4) the possibility of performing diﬀerent analyses, including microbiological quantitative, microscopy and molecular analyses, to obtain more complex results.[132–134] For a notable example, Harrison and Diggle demonstrated an optimized ex vivo model of cystic ﬁbrosis
(CF) lung infection by culturing pig bronchiolar tissue in artiﬁcial CF mucus.[135] They focused on the formation of P. aeruginosa bioﬁlms. As shown in Figure 3A, the CF isolates established bioﬁlms on bronchiolar tissue much faster and more speciﬁc than the laboratory isolates. Figure 3A (I) shows the ex vivo
pig lung tissue localized in an artiﬁcial sputum medium 19 h after inoculation. The uninfected bronchioles retain their normal
appearance as pink and white squares, without apparent degeneration, surrounded by clear ASM. At this early stage, the laboratory strain PA14 showed no visible growth in tissue or in surrounding ASM. In contrast, PAO1 grew dramatically in the ﬂuid
ASM surrounding the tissue but did not yet exhibit any significant growth on the tissue itself. But CF isolates of P. aeruginosa grew as leaf-like aggregates linked to tissue cubes, showing
a signiﬁcant diﬀerence when compared with the dense planktic
growth of PAO1. Figure 3A (II) shows CF isolates of P. aeruginosa (three replicates of SED-41 and SED-43 each) grew to high
density on EVPL 4 days after inoculation. Figure 3A (III) shows
these bioﬁlms were distinctly mucilaginous. There was no visible
P. aeruginosa PA14 growth either on the tissue or in the surrounding ASM for 19 h after inoculation. When culturing P. aeruginosa
PAO1 and the CF isolates for the same period of time, there was
visible bacterial growth. Even PAO1 grew avidly in the ASM surrounding the tissue, there was no noticeable growth on the tissue
surface during the initial stage. On the contrary, after inoculation
for 19 h, the CF isolates established frond-like agglomerates attached to the tissue surface without detectable cloudiness of the
adjacent liquid medium. These ﬁndings were in line with ex vivo
pig lung tissue, and therefore provide a practical model environment for the lung-adapted clones. In another study, Schaer et al.
showed that S. aureus bioﬁlm aggregates were established among
all tested species after infection for 24 h (Figure 3B (I)).[136] SEM
images suggested that bioﬁlm aggregates displayed almost identical morphological features in equine, porcine, and human synovial ﬂuids. S. aureus encased in a polymeric, cord-like ECM
was noticed in every species (Figure 3B (II)). 3D reconstruction of confocal microscopy images indicated bioﬁlm aggregates
from synovial ﬂuid showed a mixed protein stained with SYPRO
in red, carbohydrate ECM stained with wheat germ agglutinin
(WGA) in blue, and nucleic acid/bacterial stained with SYTO9
in green distributed through the aggregate in each species
(Figure 3B (III)).

2.3. In Vivo Bioﬁlm Models
Although this is a rapidly developing area of research, much
about bioﬁlm formation and behavior remains unknown, especially in the in vivo situations. Due to the pressing need for
new chronic wound therapies, understanding the complexities
of bioﬁlm-infected wounds is extremely important.[137] Studies in understanding the interaction between bioﬁlm properties
and host inﬂammation are important to ameliorate this body-of-
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knowledge. Especially, the interplay between bacteria and host,
namely the wound bed itself, accounts for part of the delineating characteristics of chronic wounds. This interaction cannot
be assessed by in vitro bioﬁlm models and analyses. Even if in
vitro studies yield basic knowledge on bioﬁlm resistance and survival mechanisms (e.g., bioﬁlm inhibition of proliferation of keratinocytes), understanding the diverse and complex interactions
between bioﬁlms and wound-healing pathways is diﬃcult from
in vitro studies alone.[138]
The absence of good in vivo models makes it hard to accurately simulate clinically wound bioﬁlms. Human studies are
logistically diﬃcult and ethically impossible, which makes animal models the only viable substitute for systematically regulating clinically related bioﬁlms. The use of animal models enables many experimental and analytical iterations that human
research cannot aﬀord, while enabling a closer approximation
of bioﬁlm-host interactions which cannot be obtained in in vitro
models.[139] In addition, in vivo modeling allows for a direct understanding of the parallel pathways and mechanisms in human bioﬁlm infections, and the translation of such information
may guide more clinical studies.[140] Thus, eﬃcacious in vivo
models are expected to inform more scientiﬁc understanding of
bioﬁlms, as well as oﬀer a basis and method for systematic examination of bioﬁlm-infected wounds in an accurate and quantitative
method.[141]
Another useful in vivo model is associated with bioﬁlms
formed around medical implants. The formation of bioﬁlms
renders conventional antibiotics and immune responses
ineﬀective.[142] Bostrom et al. used C57BL/6 mice with implantation of a unilateral proximal tibial graft and intra-articular
injection of S. aureus Xen 36 to establish an in vivo periprosthetic joint infection model.[143] Autopsy of the infected knees
in animals that underwent euthanasia at week 2 showed deformed soft-tissue planes, pyogenic intra-articular material,
peri-implant bone erosion, and a loose implant (Figure 4A). At
week 6, autopsy of the euthanized animals displayed extensive
bone impairment and a loose implant. Contrarily, the controls
showed an integration between bone and implant. In a diﬀerent
study, Van de Vyver et al. built a vascular graft infection model
that closely mimicked the human environment by inserting a
catheter into the right carotid artery of mice and inoculating 8
diﬀerent S. aureus strains intravenously.[144] The ﬂuorescence
in situ hybridization (FISH) analysis was applied to detect
ribosomal RNA on the surface of vascular grafts in order to
provide information regarding the diﬀerences in vivo and in
vitro bioﬁlm formation. Bioﬁlms formed on a catheter in vitro
were compared with those in the mouse infection model. FISH
analysis of the in vitro-grown bioﬁlm on the catheters indicated
the formation of multilayer bioﬁlms on the external surface
with a high number of bacteria dictated by bright FISH signals
(Figure 4B). Moreover, FISH analysis of in vivo and in vitro
catheters validated the formation of multilayered homogeneous
bioﬁlms in all studied samples. In the in vivo model, bacterial
communities were mainly present at the blood-graft contact site
(e.g., the luminal surface of the catheter). Signiﬁcant diﬀerences
were observed in the structure of bioﬁlms grown in vivo compared to in vitro bioﬁlms, in which a large number of host cells
fused with the matrix and bacteria. The number of FISH positive
bacteria diﬀered from FISH signal strength and was lower in
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Figure 3. Two representative ex vivo bioﬁlm models. A) An ex vivo lung model to study bronchioles infected with P. aeruginosa bioﬁlms. I): EVPL in situ
in ASM at 19 h post-inoculation. Uninfected bronchiolar tissue retained its normal appearance: a pinkish-white square with no noticeable degradation,
surrounded by clear ASM. The laboratory strain PA14 did not show visible growth either on the tissue or in the surrounding ASM at this early stage;
PAO1, in contrast, had grown extensively in the liquid ASM surrounding the tissue (green-yellow pigmentation due to production of pyoverdine) but did
not yet show any noticeable growth on the tissue itself-note pinkish-white square of tissue sitting in the liquid bacterial culture. In contrast, CF isolates
of P. aeruginosa (e.g., SED-41 and SED-43) showed growth as frond-like aggregates on and connected to the cubes of tissue, very diﬀerent from the
dense planktonic growth of PAO1. II) By 4 days post-inoculation, CF isolates of P. aeruginosa had grown to a high density on EVPL. The image shows
three replica infections of SED-41 (top row) and SED-43 (bottom row) after washing the tissue with phosphate-buﬀered saline to remove non-adhering
cells: a coating of sticky P. aeruginosa, with blue-green pigmentation (pyoverdine and pyocyanin), was left behind. III) These bioﬁlms were noticeably
mucoid (e.g., SED-41). Reproduced with permission.[135] Copyright 2016, Microbiology Society. B) S. aureus forms macroscopic bioﬁlm aggregates in
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catheters from in vivo models. Low FISH signals from bacteria
in the body can be attributed to stationary or stationary patterns
and may lead to increased resistance to antibiotic therapy in
clinical settings. In addition, the static growth patterns in these
bioﬁlms led to decreased susceptibility to the immune system.
These results highlight the relevance of the in vivo vascular graft
model, because it more closely represents a true in vivo situation
where bacterial metabolism is inﬂuenced by the immune system
and blood ﬂow.

3. Potential Targeting Strategies in Combating
Bioﬁlms
A greater knowledge of the molecular compositions and functions of bioﬁlms would be helpful in ﬁnding reasonable methods for prevention and treatment. Figure 5 shows the compositions and functions of bioﬁlms in structured microbial
communities.[145] Figure 5A shows ﬂuorescent images of formed
cross-kingdom dental bioﬁlms within ECM, and the inset

the synovial ﬂuid of several diﬀerent species. Equine, human or porcine synovial ﬂuid was infected at 1×106 CFU/mL with S. aureus (ATCC25923) and
incubated overnight at 37 °C in a microaerophilic chamber on a shaker at 120 rpm to mimic the joint environment. I): Macroscopic bioﬁlm aggregates
were observed in synovial ﬂuid in all three species and photographed. II): Aggregates were removed from the synovial ﬂuid, ﬁxed, dehydrated in ethanol,
sputter coated, and imaged with an SEM, showing bacteria nested within a polymeric cord-like ECM. III) Aggregates were stained with WGA in blue
for carbohydrates, SYTO9 in green for nucleic acids, and SYPRO in red for proteinaceous content. 3D CLSM images were reconstructed by sequential
Z-stacking and tile scanning with Velocity software. Reproduced with permission.[136] Copyright 2019, PLOS.

Figure 4. Two representative in vivo bioﬁlm models. A) Photographs showing right knees of C57BL/6 mice after surgical implantation for 6 weeks. I): In
the control animal, anatomical structures were preserved, with clear visualization of the patella and patellar tendon. II): In the animal infected with S.
aureus, the patella was diﬃcult to identify on superﬁcial dissection. The underlying joint capsule (arrow) was distended because of being full of purulent,
foul-smelling, yellow material. III): Upon entering the joint, the proximal aspect of the tibia was fragmented and friable. The implant (arrowhead) was
found within soft bone, was grossly loose, and was covered with yellow intra-articular material (arrow). Reproduced with permission.[143] Copyright 2017,
The Journal of Bone and Joint Surgery, Inc. B) Fluorescence in situ hybridization (FISH) of in vitro grown S. aureus LS1 bioﬁlms on a polytetraﬂuoroethylene
catheter. The section was hybridized with the pan-bacterial probe EUB338FITC (green), S. aureus speciﬁc probe SAUCy3 (yellow), nonsense probe
NON338 (magenta), and nucleic acid was stained with DAPI (blue). I): Overview of the bioﬁlm located on the outside of the catheter, showing multilayered
cocci with strong ﬂuorescence signals. II): High magniﬁcation image of boxed area in (I) showing merged image of all channels, indicating multilayered
cocci with strong FISH signals. III–V): Black and white images of the single ﬂuorescence channels showing nucleic acid staining with DAPI (III), panbacterial probe EUB338FITC (IV), and S. aureus speciﬁc SAUCy3 signals (V). Note that all bacteria stained with EUB338 also show signals with probe
SAUCy3. Reproduced with permission.[144] Copyright 2017, Elsevier.
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Figure 5. Compositions and functions of bioﬁlm matrix in structured microbial communities. A) confocal ﬂuorescence images of developed crosskingdom dental bioﬁlms within ECM (red); inset shows Streptococcus mutans (green)-Candida albicans (cyan) interactions mediated by ECM (white
arrows). B) 3D reconstruction of CLSM images of in vitro oral bioﬁlms after matrix staining. C) A schematic representation of the main components of
the bioﬁlm matrix and their functions. The bioﬁlm matrix consisting of a wide array of functional biomolecules serves as a scaﬀold for structural support
and a dynamic milieu that provides varying chemical and physical signals to microbial communities, promoting a bioﬁlm lifestyle. Reproduced with
permission.[145] Copyright 2020, Elsevier.

indicates ECM-mediated interactions between Streptococcus mutans and Candida albicans. Figure 5B shows a 3D reconstruction
CLSM image of an in vitro oral bioﬁlm after matrix staining. Figure 5C shows a diagram of the major compositions and functions
of bioﬁlm matrix. It is made up of a diverse set of structures and
molecules. It acts as a scaﬀold for structural support as well as
a layout to facilitate various physical and chemical cues amongst
the microbial community to promote the adoption of a bioﬁlm
lifestyle. Bioﬁlms hold the ability to create distinct microenvironments with exclusive physical, chemical, phylogenetic, genotypic,
and phenotypic heterogeneities. Earlier therapeutic approaches
to treat bacterial infections by targeting individual cells had limited success. Currently, we have a better understanding of bioﬁlm
biology. Microbial bioﬁlms represent a dynamic self-constructed
ecosystem within a matrix containing a highly heterogeneous
and compartmentalized milieu, and more eﬀective antibioﬁlm
therapies probably need to target the complete microenvironment, as well as the individual cells within. Based on the com-
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positions and functions, four potential targeting strategies could
be used for the prevention and treatment of bioﬁlms in theory.

3.1. EPS-Targeting Strategies
The EPS composition in diﬀerent bioﬁlms shows temporospatial variations, which is subject to the strain of microorganism, regional mechanical shear force, substrate readiness, and
host environment.[146] EPS enhances microbial adhesion to surfaces, intercellular adhesion, and cell aggregation, and acts as
a 3D scaﬀold to protect against host eﬀectors and antibacterial therapy.[147] In addition, EPS matrices can change chemical
and nutritional gradations and map the pathogenic environment
(e.g., pH and hypoxia), which contributes to important virulence
properties.[148,149] Therefore, the EPS matrix is a favorable target for the destruction of bioﬁlms, as doing so would decompose bacteria and degrade the pathogenic environment. Anti-EPS
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strategies include inhibition of EPS production, prevention of
microbial adhesion to the EPS matrix by inhibiting EPS adhesion, or degradation of EPS in established bioﬁlms. For instance,
DNase is eﬀective in cleaving extracellular DNA (eDNA) of bacterial bioﬁlms.[150]

3.2. Inducing Bioﬁlm Dispersal
Bioﬁlm dispersal is regulated and involves the degradation of
EPS. Artiﬁcially triggering this reaction is the subject of many
research strategies aimed at promoting the self-decomposition
of bioﬁlms.[151] In most cases, these methods postulate that dispersed bacteria have reverted to their more metabolically active
planktonic state, which makes them more susceptible to conventional antibiotics.[152] In addition, the released dormant cells
would also lose protection due to their association with bioﬁlm
communities and structural tissues.[153] Despite their dispersed
state, it is still critical to dose dispersed or exogenous EPS bactericides with systemic antibiotics in a clinical setting to avoid
recolonization, bacteremia, or sepsis.[154]

3.3. Metabolic Interference
There is considerable interest in the use of exogenous
amino acids for bioﬁlm therapy, and some amino acids
have been demonstrated to inﬂuence bioﬁlm metabolism and
maturation.[155] L-arginine can be used as a substrate for arginine decomposition bacteria (such as Streptococcus gordonii (S.
gordonii)) to produce alkali. It has been proved clinically that LArg can neutralize acid and regulate the pH homeostasis in oral
bioﬁlm.[156] Treatment with L-Arg of polymicrobial bioﬁlms containing Streptococcus mutans (S. mutans), S. gordonii, and Actinomycetes endrogeni inhibited the growth of S. mutans and led
to a signiﬁcant decrease in insoluble EPS as well as changes in
the structure of the bioﬁlm. Other than pH regulation, L-Arg
can also inhibit genes associated with the generation of insolvable EPS and bacteriocins in S. mutans, meanwhile promoting
the production of hydrogen peroxide (used against S. mutans)
by S. gordonii. L-Arg lowered the total biomass and rearranged
EPS structure in S. gordonii bioﬁlms. It also destabilized multiple species oral bioﬁlms, thereby reducing the viability and
increasing sensitivity to cetylpyridinium chloride.[157] Another
amino acid, L-methionine (L-Met), has also been recognized as
an encouraging supplemental therapy for treating P. aeruginosa
bioﬁlms, as it triggered decomposition and increased sensitivity
to ciproﬂoxacin in a mouse model of chronic pneumonia, and
improved survival in infected mice.[158] This activity is ascribed
to the upregulation of four diﬀerent DNase genes. Activation of
these genes leads to the enzymatic destruction of eDNA in the
EPS matrix, although the exact pathway that regulates this reaction has not been determined. Interestingly, L-Met has been
identiﬁed after screening for the activity of D-amino acids and
L-amino acids against P. aeruginosa bioﬁlms. Because of the versatility of amino acids used among bacterial species, a single
amino acid is not likely to have the same function across bacterial species. Isoleucine has been shown to induce the expression of antimicrobial peptides (AMPs) that help inhibit bacteria

Adv. Sci. 2022, 9, 2203291

and bioﬁlms.[159] Therefore, the essential role of amino acids in
bacterial metabolism and host defense should not be discounted
from further research for therapeutic strategies.[160,161]
Another approach to metabolic interference stems from evidence that has shown iron metabolism to be critical for the
bioﬁlm formation of several pathogenic microbes.[162–166] Iron
access is critical for establishing infection with pathogens, and
epithelial cells containing mutations of the CF transmembrane
conductance regulator ΔF508 suggest P. aeruginosa bioﬁlm formation correlates with increased available iron levels. Host defenses often actively try to reduce iron levels to hinder bacterial
replication, as iron is an important nutrient for bacterial growth.
To combat this, P. aeruginosa has evolved excess iron receptors
and absorption systems (e.g., siderophore and iron chelating
molecules).[167] Gallium has a similar chemical feature as iron
and can be absorbed by bacteria but fails to substitute the function of iron. Therefore, when it is taken up, it inhibits irondependent pathways necessary for bacterial growth and bioﬁlm
formation.[168] This “Trojan horse” approach has been shown to
interfere with the growth and iron metabolism of P. aeruginosa,
kill phytoplankton in the acute mouse pneumonia model, and
reduce the number of bacteria in established bioﬁlms by a factor of 1000 in the chronic bioﬁlm lung infection model.[162] Gallium is taken by inhaling. Its absorption by bacteria in vitro is
not dependent on the presence of the P. aeruginosa siderophore
Pyoverdin. In vivo, however, any additional anti-inﬂammatory effects that gallium may have on the host beyond direct inhibition
of bioﬁlms are not clear.

3.4. Targeting Cells in Bioﬁlms
Processes such as bioﬁlm dispersal induction through targeted
pathways require the cells to undergo metabolic activity. However, some evidence also suggests that persistent substances residing in bioﬁlms are important in drug resistance.[169] Therefore, antimicrobial approaches that consider physical or chemical damage to cells rather than targeting speciﬁc cellular processes are attractive. Non-discriminatory oxidants (e.g., hypochlorite and hydrogen peroxide) have been applied as rinsing agents
for wound and endodontic debridement.[170] Nevertheless, studies have shown that even strong oxidants like sodium hypochlorite cannot completely remove bioﬁlms likely due to inadequate exposure given the cytotoxicity.[171] Wide-spectrum cationic
biguanides like chlorhexidine[172] or quaternary ammonium,[173]
could attach to cell walls and damage membranes. However,
these substances penetrate minimally over the time-ranges used
in in vitro dental bioﬁlms, and long-term exposure is cytotoxic,
which makes this strategy unfeasible in clinics

4. State-of-the-Art Technologies for Prevention and
Treatment of Bioﬁlms
4.1. Prevent Bioﬁlm Formation
For a long time, the prevention of bioﬁlm formation has been
a hot topic in the research ﬁeld. The ﬁrst important role in preventing bioﬁlm formation is to prevent bacteria from attaching to
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host tissue in order to inhibit infection. This is an enticing therapeutic target for preventing bacterial infection, and multiple approaches have been reported.[174] These methods include hindering cell receptors from recognizing adhesive surfaces, inhibiting
bacterial adhesion processes, and blocking primary colonizers to
hinder the original formation of the bioﬁlm and prevent any future infectious spread by planktonic cells released by the bioﬁlm
itself.[175]

4.1.1. Bioﬁlm Inhibition by Quorum Quenching
Quorum-sensing (QS) is a system that Gram-negative and grampositive bacteria use to communicate.[176] QS modulates the activity of various genes by detecting the concentration of signaling molecules within the bacteria’s environment. The signaling
molecules in the QS system are denoted as autoinducers.[177]
QS signaling molecules can be classiﬁed into 3 types: Nacyl homoserine lactones (AHLs)-based (Gram-negative bacteria), autoinducing peptide-based (Gram-positive bacteria), and
autoinducer-2 (AI-2)-based (both Gram-negative and Grampositive bacteria).[178] During the bioﬁlm formation, cells secrete
QS molecules after initial attachment. These molecules induce
changes in gene expression to transform bacteria from a planktonic lifestyle into a sessile form.[179] Because QS is so important for the construction of bioﬁlms, it has been proposed that
QS inhibition (quorum quenching (QQ)) could be used for the
prevention of bioﬁlms.[180] Furthermore, QS is important for the
expression of many important virulence factors, thus the QS system can be thought of as a promising and novel antimicrobial
target.[181] The main advantage of using QQ to control bioﬁlms is
that it lowers the chance of multidrug resistance. Therefore, this
strategy has important clinical signiﬁcance for the prevention of
bioﬁlms.[182]
According to the size and chemical makeup, QQ agents can
be classiﬁed into two groups: macromolecular QQ enzymes[183]
and microparticulate QS inhibitors.[184] Enzymatic destruction of
AHL molecules is the most noted mechanism of QQ. Many enzymes can catalyze this degradation, but all fall into four distinct classes: lactonases and acylases that hydrolyze the HSL
ring and amide bond of AHL, while reductases and oxidases
that change the activity of AHL molecules, but do not break
down them.[185] Another important QQ mechanism is using
compounds to antagonize QS inductors; these molecules bind
to receptors to prevent the QS signal from being recognized
by the cell. Inductor antagonism may be competitive or noncompetitive.[186] The last mechanism is inhibiting intracellular signal transduction cascades. It has been demonstrated that
savarin, a small molecule inhibitor, disturbs AgrA, a transcriptional regulator of the QS-involved agr operon, by binding DNA
to inhibit the production of RNAIII which contributes to the
expression of multiple virulence factors in combination with
AgrA.[187]

4.1.2. Surface Modiﬁcations
Implant-related infections and nosocomial infections not only increase medical costs, but also threaten the health and lives of
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patients. Treatment of these infections is challenging.[188] Despite the best eﬀorts of medical staﬀ to prepare clean areas
during surgical implantation, implant-associated infections continue to persist. Bacterial attachment to the implant is the initial step of the process, succeeded by aggregation of the bacteria
to form bioﬁlms that lead to infection. Because of the existence
of dense ECM produced by bacteria, the diﬀusion of antibacterial agents into bioﬁlms is limited, leading to poor therapeutic
eﬃcacy and bacterial resistance. Bioﬁlm-protected bacteria may
also be released, leading to new sites of infection.[189] It has been
shown that eradicating such protected pathogens is nearly impossible. Hence, infected implants must be removed in order to
prevent transmission of infection. Considering the consequences
and complications of implant-associated infections, the best approach to care is to prevent infections instead of treating them
after they have emerged.[190]
One potential way to avoid implant-related infections is to
modify the surface of implants with a bacterial-repellent layer.
This layer prevents early bacteria from attaching to the implant
surface, which in turn prevents bioﬁlm formation.[191] Over the
years, a number of surface modiﬁcation strategies have been
reported for producing coatings with anti-infective activity. At
present, anti-infection modiﬁcation methods include antifouling
material coatings, embedding of antimicrobial therapeutics, and
contact-killing coatings. These methods apply general principles
including inhibiting bacterial adhesion to surfaces, destroying
bacteria on surfaces, and hindering bacterial growth from the implant surface.
Hydrophilic polymer brush-based coatings have been a subject of interest; they are resistant to bacterial adhesion due to
non-fouling and protein-repellent properties. It has been diﬃcult, however, to translate such coatings into medical devices, especially devices made of polymeric materials.[192] Su et al. synthesized a block copolymer that combines anti-infective, antifouling, and surface-conjugating properties into one molecule and
conjugated it to polymeric substrates (Figure 6A).[193] The coatings exhibited high antimicrobial eﬃcacy against gram-positive
bacteria, gram-negative bacteria, and fungi. It demonstrated excellent antifouling activity and was re-usable for long-term. Furthermore, the coatings greatly decreased the number of bacteria with 100 000-fold bacterial reductions in a rodent subcutaneous infection model. Hydrogel coatings have also shown considerable promise, as they have good resistance to protein adsorption and inhibit the bioﬁlm formation of many diﬀerent
bacterial strains. In another work, Su et al. synthesized a novel
biomimetic surface-attachable initiator through the conjugation
of 3, 4-dihydroxyphenylacetic acid and thermal 2, 2′-azobis (2methylpropionamide) dihydrochloride.[194] The synthesized initiator can attach to diﬀerent surfaces like a mussel and initiate
surface conjugation (Figure 6B). Hydrogel coatings were synthesized through copolymerization of polyhexamethylene guanidine
(antimicrobial) and polyethylene glycol (antifouling) oligomers.
In vitro testing of these coatings revealed antimicrobial activity.
They were eﬀective against bioﬁlms and had low cytotoxicity. The
anti-microbial activity of these hydrogels was especially eﬃcacious, with a greater than 5-log reduction in a rodent subcutaneous infection model.
AMPs are another potential solution for the prevention of indwelling device infections and may be an alternative to anti-
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Figure 6. Typical examples of antimicrobial surface coatings. A) Polymer brushes-based coatings. Reproduced with permission.[193] Copyright
2017, Wiley-VCH. B) Anti-adhesive hydrogels. Reproduced with permission.[194] Copyright 2019, Wiley-VCH. C) AMP conjugates. Reproduced with
permission.[197] Copyright 2015, Elsevier. D) Nanopillar array coatings. Reproduced with permission.[204] Copyright 2017, American Chemical Society.
E) Nanocomposite coatings. Reproduced with permission.[206] Copyright 2019, American Chemical Society.
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microbial coatings. AMPs have broad-spectrum anti-microbial
activity against bacterial species, fungi, and even viruses. AMPs
have been demonstrated to be biocompatible in many assays.[195]
The titanium surface covalently coated with the major AMP
of human cathelicidin LL-37 is eﬀective against the ESKAPE
pathogens (Enterococcus faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter species).[196] In a diﬀerent study, Leong et al. reported a simple and eﬀective method
to immobilize a potent synthetic AMP, CWR11, onto catheterrelevant surfaces.[197] Polydopamine (PD) was coated onto a polydimethylsiloxane (PDMS) surface as a thin adherent ﬁlm to facilitate the attachment of CWR11 onto the PD-functionalized
polymer (Figure 6C). The CWR11-functionalized PDMS slides
showed high levels of antimicrobial and antibioﬁlm activity. The
CWR11-embedded catheter was potently toxic to bacteria and retained bactericidal for at least 21 days.
Research has reported that the wing surface of insects like
the cicada and dragonﬂy have excellent antibacterial activity.[198]
Nanopillars on the surface of wings serve as sharp needles
that result in holes in the bacterial wall and death of the bacterium. Synthetic replications of these nanopillars with diﬀerent materials have shown potent bactericidal activity skin to
dragonﬂy and cicada wings.[199–203] Sen et al. fabricated sharptipped nanostructures on silicon surfaces (NSS) utilizing the
maskless deep reactive ion etching mimicking dragonﬂy wings
(Figure 6D).[204] Antimicrobial eﬃcacy of the nanostructured
surfaces coated with a thin layer of silver (NSS_Ag) or copper (NSS_Cu) was quantiﬁed. NSS_Cu surfaces killed bacteria more eﬃciently relative to the uncoated NSS. This could
be due to the metal ions eluted from coatings and biomimetic
nanostructures.
Additional strategy to prevent infections from forming on devices is to incorporate antimicrobial agents directly to kill bacteria. One such strategy is to load device coatings with metallic
nanoparticles which release metal ions at a bactericidal concentration to eliminate any bacteria around the surface.[205] Boccaccini et al. incorporated 5 wt.% of CuO to 45S5 bioglass materials
(Figure 6E).[206] This Cu-doped bioglass served as the substrate
for the deposition of bioactive thin ﬁlms using a pulsed laser.
Anti-microbial analysis of the material revealed it to be more
eﬀective in killing Gram-negative bacteria than killing Grampositive bacteria.
It is worth mentioning that some of the surface modiﬁcation
strategies have already been approved by the US Food and Drug
Administration (FDA). Most approved therapeutics are related
to the hydrophilic coatings on medical devices. According to the
FDA website, there are 77 records of approved hydrophilic coating devices as of July 2022. Biocompatibility and durability of
hydrophilic coatings show great beneﬁts in the ﬁelds of cardiology and urology. Due to the emergence of new coating technologies, the use of hydrophilic coatings in the medical ﬁeld has
increased. With its disposable capacity, devices with hydrophilic
coatings are also used in emergency departments and delivery
units in medical institutions, while other common devices with
hydrophilic coatings are used in the ﬁelds of endoscopy and respiratory care.[207] There are also 13 records of approved hydrogelcoated devices, another FDA-approved surface modiﬁcation strategy for medical devices. In addition, there are 4 records of approved antimicrobial coated devices.
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4.2. Eradicate Existing Bioﬁlms
4.2.1. Physical Methods
Non-Thermal (Cold) Plasma: Use of non-thermal discharge
plasmas is one of the physical methods to destroy bioﬁlms. Cold
plasma has several distinct advantages compared to traditional
sterilization methods because it contains free radicals, charged
particles, UV photons, and other reactive substances that are eﬃcient at killing microorganisms.[208] Plasma is produced by transferring energy, usually in the form of an electric discharge, into
adjacent gas. This energy excites gas particles from their ground
state and changes their electron arrangement.[209] Plasma is produced most often by the application of an electric ﬁeld to a neutral gas. When energy is suﬃcient for both electrons and heavier
molecular species, the produced plasma is referred to as “thermal plasma”. Conversely, if the energy level of the electrons is
higher than the heavy molecular species, the plasma is known
as “cold” or “non- thermal”.[210] The ability to produce the active agents at ambient or near ambient temperatures (≤ 25–30
°C) and at atmospheric pressure without any vacuum system is
a distinct advantage. This is especially pertinent in biomedical
applications, because samples cannot be placed inside vacuum
chambers. Using plasma for sterilization does not pose any serious health risks for either the operator or the patient and is thus
considered safe.[211] Besides, the many diﬀerent reactive species
found in plasma likely exert a synergistic eﬀect to increase the
eﬃcacy of plasma sterilization. Even at low levels, these reactive
compounds have been known to damage or destroy microorganisms. Plasma is generated using air, so using it for sterilization
is very cost-eﬀective.[212]
A considerable amount of research has investigated the use
of non-thermal plasma (NTP) (e.g., corona discharge, microwave
discharges, plasma jet, gliding arc, and dielectric barrier discharge) in the treatment of bioﬁlms (Figure 7A).[213] One interesting and notable use of plasma is for the deactivation of
oral bioﬁlms. Dental plaque bioﬁlms are made up of a diverse
and complicated community of oral microbes; the ability of
these communities to cause cavities and gum disease is well
known.[214] One of the plasma devices for combating these oral
bioﬁlms is a plasma needle. It was examined against cariogenic
Streptococcus mutans in a simulated cavity model, the penetration of the active plasma compounds was measured along with
levels of bacterial inactivation.[215] Sixty seconds of treatment at
110 and 340 mW power produced a 5–8 mm radius of bacterial inactivation. A diﬀerent work involved with the use of positive and negative corona discharges on bioﬁlm-contaminated
tooth surfaces to test the eﬃcacy of water electrospraying for
decontamination.[216] Both types of discharges greatly reduced
bacterial concentrations. The magnitude of the reduction correlated with treatment time, the bacterial concentration was reduced by 1–1.3 logs and 2.73 logs at 5 and 10 min. Additionally,
water electrospraying via the plasma decreased bacteria by 3.16
orders of magnitude. The treatment was not observed to cause
any signiﬁcant changes to tooth surfaces. In another work, Koban
et al. examined the eﬀect of three devices including an atmospheric pressure plasma jet, a hollow dielectric barrier discharge
electrode, and a volume dielectric barrier discharge against dental bioﬁlms.[217] The analysis revealed the devices reduced S.
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Figure 7. Typical methods of the physical removal of bioﬁlms. A) Non-thermo plasma. Reproduced with permission.[213] Copyright 2018, Elsevier. B)
Microbubbles. Reproduced with permission.[227] Copyright 2018, American Chemical Society. C) Photothermal therapy. Reproduced with permission.[236]
Copyright 2019, Elsevier. D) Ultrasound transducer. Reproduced with permission.[241] Copyright 2019, John Wiley & Sons Ltd and Society for Applied
Microbiology. E) Magnetically driven active topography. Reproduced with permission.[247] Copyright 2020, Springer Nature. F) Catalytic antimicrobial
robots. Reproduced with permission.[257] Copyright 2019, American Association of the Advancement of Science. G) Electrical stimulation. Reproduced
with permission.[260] Copyright 2015, Springer Nature. H) Pulsed electric ﬁelds. Reproduced with permission.[263] Copyright 2016, Wiley-VCH.

mutans and saliva bioﬁlm levels between 5.38 and 5.67 logs.
Chlorhexidine (CHX) was used as a control, showing a logreduction of 3.36 and 1.50 on the same bioﬁlms. Additionally,
a 5-log reduction was obtained on Candida Albicans bioﬁlms.
These results indicated that plasma seems to have higher efﬁcacy than CHX in treating single and multispecies dental
bioﬁlms.
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NTP could also provide a diﬀerent method for sterilizing and
decontaminating the inner surfaces of medical devices. Implants
are vulnerable to infections, and infection is one of the principles
which cause implant failure. Therefore, sterilization methods are
critical for the success and performance of an implant.[218] Ercan et al. assessed the inactivation and inhibition of bioﬁlm formation of E. coli and S. aureus on UHMWPE, Ti6A14V, 304 SS,
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and 316L SS surfaces, which are used for acetabular cups and
inserts in total knee prostheses.[219] Plasma treatment of these
discs inactivated 95% of bacterial bioﬁlms after three min of treatment. In a separate study, Matos et al. showed that glow discharge plasma treatment of titanium-based dental implants increased their wettability.[220] The treated surfaces did not show
any increase in the proliferation of a multi-species (Streptococcus
sanguinis, Actinomyces naeslundii, and Fusobacterium nucleatum)
bioﬁlm. In their continuous study, Matos et al. used the glow discharge plasma method to deposit CHX-doped thin ﬁlms on pure
titanium (cpTi).[221] CHX release was sustained for more than 22
days, leading to a signiﬁcant suppression of bioﬁlm formation at
48 and 72 h for 50 and 20 min of plasma deposition, respectively.
Microbubbles: Microbubbles are micron-sized bubbles of gas
enclosed by a thin layer of lipid or surfactant-based substance.[222]
Microbubbles were reported by Charles Joiner for the ﬁrst
time in the late 1960s, who found their existence during an
echocardiogram.[223] After dozen years, microbubbles were developed as ultrasound contrast agents.[224] Fundamentally, microbubbles consist of gases with a high molecular weight stabilized by an outer lipid monolayer. Insoluble gases like ﬂuorinated
carbon or sulfur compounds, (e.g., sulfur hexaﬂuoride and decaﬂuorobutane) typically make up the gas core and increase the
stability of the microbubble.[225]
It has been demonstrated that microbubbles can be used to disrupt bioﬁlms. Liu et al. compared the microbubble-mediated detachment of bioﬁlms from a nylon membrane to chemical cleaning with sodium hypochlorite (NaOCl).[226] Roughly 88% of the
ﬁxed biomass was detached after 1 h of microbubbling. Contrarily, around 10% of the biomass was detached in the control
experiment that did not utilize microbubbling. CLSM images
conﬁrmed a complete disruption of EPS, as the images clearly
showed an almost total removal of bioﬁlm extracellular polysaccharides and proteins. In another work, Kong et al. hypothesized
that engineered microparticles carried by microbubbles could remove a bioﬁlm from a structure by fracturing the EPS and increasing the delivery of antiseptic agents (Figure 7B).[227] In order to test this hypothesis, they applied manganese oxide (MnO2 )
nanosheets to a hollow-cylinder-shaped diatom biosilica. In an
H2 O2 solution, the diatoms doped by MnO2 nanosheets, known
as the diatom bubbler, released oxygen bubbles and generated
self-motion. Then, the diatoms penetrated the bioﬁlms grown on
either ﬂat or microgrooved silicon substrates and kept on producing microbubbles. The microbubbles produced by this process
merged, generating enough mechanical energy to break up the
bioﬁlm matrix. This allowed H2 O2 molecules to diﬀuse into the
bioﬁlm and kill bacteria.
In addition, microbubbles have demonstrated the ability to improve treatment by increasing a bioﬁlm’s susceptibility to drugs.
Zhang et al. demonstrated that, when human 𝛽-defensin 3 (hBD3) was applied together with microbubble destruction, bioﬁlm
density was reduced and the number of living cells from two
tested Staphlococcus strains was signiﬁcantly decreased when
compared with other groups.[228] It was also shown that microbubble destruction may boost hBD-3 activity by hampering
the bioﬁlm-associated gene expression (icaAD), decreasing expression of methicillin resistance gene (MecA), while also increasing icaR expression. In another work, Wang et al. reported
that microbubble destruction damaged the cell wall structure of
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S. epidermidis, which is evidenced by TEM images of ﬂoccules
and fragments from damaged cells.[229] Although the cell membrane was almost intact, the treatment caused an increase in the
metabolic activity of bacteria within the bioﬁlm. These changes
observed by CLSM and ﬂow cytometry could make them more
susceptible to antibiotic killing.
Photodynamic and/or Photothermal Therapy: Antimicrobial
photodynamic and/or photothermal therapies are promising local strategies for the treatment of antibiotic-resistant bacterial infections and bioﬁlms.[230,231] Over the last few decades, photodynamic therapy (PDT) and photothermal therapy (PTT) have
emerged and demonstrated increasing potential in managing
bacterial infections partially because of the advances in the synthesis of photosensitizers (PS) /photothermal agents (PTAs).
PDT or PTT works by transforming light energy into reactive oxygen species (ROS) or heat, leading to membrane breakup, protein
denaturation, and permanent bacterial damage.[232,233]
Herein, we highlight several notable studies on the use of PDT
and/or PTT for bioﬁlm treatment. Some studies described the
application of PDT and/or PTT for the treatment of bioﬁlms
in vitro. Sayar et al. assessed the eﬃcacy of PDT with toluidine blue (TBO) and indocyanine green (ICG) using 635 nm
alongside 808 nm diode lasers in the treatment of Aggregatibacter actinomycetemcomitans bioﬁlms grown on Laser-Lok titanium
discs.[234] There was a signiﬁcant diﬀerence in the number of
bacterial colonies present in the diﬀerent groups after the intervention. PDT with TBO+635 nm and ICG+808 nm laser treatment signiﬁcantly reduced bacterial count relative to the control group. TBO alone also signiﬁcantly reduced the bacterial
count as compared with the control group. In a separate study,
Bilici et al. combined nanoparticles and organic photosensitizers for eﬃcient removal of planktonic bacteria and their corresponding bioﬁlms.[235] In Kirui et al.’ study, the photoinduced
antimicrobial activity of ICG, 3-aminopropylsilane coated superparamagnetic iron oxide nanoparticles (APTMS@SPIONs),
and ICG loaded APTMS@SPIONs were tested against planktonic bacteria and bioﬁlms. Successful eradication of bioﬁlms
was seen with ICG/laser or ICG-loaded APTMS@SPION/laser
treatment. A dramatic 6.5-log reduction in CFUs was observed
between ICG versus ICG-loaded APTMS@SPION treatment
against K. pneumoniae bioﬁlms. They also demonstrated that the
gold nanoparticle-targeted pulsed laser therapy can promote the
eﬃcacy of antibiotics in treating MRSA and multidrug-resistant
P. aeruginosa bioﬁlms in vitro (Figure 7C).[236]
Furthermore, many studies have been performed by applying
PDT/PTT to remove bioﬁlms in vivo. Yuan et al. presented a
phototherapeutic nanoplatform consisting of L-arginine (L-Arg),
ICG, and mesoporous polydopamine (MPDA), speciﬁcally, AIMPDA, to combat bioﬁlms.[237] Upon NIR irradiation, the bioﬁlm
removal was caused by the nitric-oxide boosted PDT and lowtemperature PTT (≤ 45 °C). This strategy led to severe damage of bacterial membranes. NIR-irradiated AI-MPDA nanoparticles stopped bacterial colonization and led to fast healing from
contaminated wounds. Notably, the all-in-one phototherapeutic
platform was nearly 100% eﬀective at eliminating bioﬁlms from
an abscess formation model. Cui et al. designed a NIR lightdriven nanoswimmer (HSMV).[238] When irradiated by NIR light,
HSMV was self-propelled and penetrated the bioﬁlm within
5 min which was attributed to the photothermal conversion of un-
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evenly distributed AuNPs. The topical thermal energy and heattriggered release of vancomycin created a combined chemotherapy and phototherapy system. The self-propulsion of HSMV increased both the eﬀective distance of PTT and the activity of
the antibiotic, leading to a greater than 90% removal of the
bioﬁlm. Importantly, HSMV was capable of removing in vivo S.
aureus bioﬁlms after 10 min of laser irradiation without damaging healthy tissues. PDT/PTT would also be an ideal approach
for the elimination of bioﬁlms in biomedical implants. Tan et al.
explored the photothermal ability of a red-phosphorus-IR780arginine-glycine-aspartic-acid-cysteine coating on titanium bone
implants.[239] The red phosphorus resulted in the production of
singlet oxygen (1 O2 ) species upon exposure to IR780 which made
S. aureus bioﬁlms more sensitive to temperature. Bioﬁlms can be
destroyed with near-infrared (808 nm) PTT in vivo without risking damage to normal tissue. Such a method can reduce 96.2%
of bacteria in vivo after irradiation at 50 °C for 10 min.
Ultrasound: The use of ultrasound for the treatment of
bioﬁlms is attractive because it does not use chemicals and is environmentally friendly. Ultrasound is high frequency (>20 kHz)
sound waves.[240] Ultrasound can produce gas cavities capable
of disrupting bioﬁlms or even inactivating microorganisms (Figure 7D).[241] On one hand, studies have been conducted on the
use of ultrasound in the removal of bioﬁlms in vitro. Granick et
al. showed that direct-contact low-frequency ultrasound was able
to eliminate S. epidermidis bioﬁlms grown on the surface of titanium and stainless steel metallic disks. The surfaces of these
alloys are similar to those used in surgical implants.[242] Crone
et al. also demonstrated that a low-frequency ultrasonic-assisted
wound debridement device was eﬀective in disrupting bioﬁlms in
vitro and further enhanced the antibacterial eﬀect of polyhexamethylene biguanide.[243] It is worth mentioning that in this study
S. aureus bioﬁlms were grown in a semi-solid agar gel consisting
of either tryptic soy broth or a wound simulating media, to recapitulate the suspended colonies. Similarly, Torlak and Sert evaluated the eﬀectiveness of ultrasound in combination with benzalkonium chloride in eliminating Listeria monocytogenes bioﬁlms
on the polystyrene surface.[244] The combined treatment resulted
in a signiﬁcantly greater reduction in the number of viable cells
in the L. monocytogenes bioﬁlms relative to individual treatments.
On the other hand, ultrasound is often used in conjunction with
other antibacterial agents to treat bioﬁlms in vivo. Yang et al. examined the anti-fungal synergism produced by combining amphotericin B (AmB)-loaded poly(lactic-co-glycolic acid) (PLGA)
nanoparticles (AmB-NPs) with low-intensity ultrasound against
Candida albicans bioﬁlms.[245] They showed that the combination
treatment of AmB-NPs with 42 kHz ultrasound produced significant reductions in bioﬁlms when compared to controls, AmB
alone, or ultrasound alone. Moreover, similar collaborative eﬀects
were observed in a rat subcutaneous catheter bioﬁlm model. The
number of CFUs on the catheter reduced signiﬁcantly after 7
days of continuous therapy with both AmB-NP and ultrasound,
revealing that the bioﬁlm on the catheter surface was severely
destroyed. In another study, to prevent spinal fusion infection,
Delaney et al. designed a polyether ether ketone (PEEK) antibiotic reservoir clipped onto the metal ﬁxation rod and achieved
sustained release of antibiotics for more than 7 days, succeeded
by a bolus release due to the rupture of the reservoir membrane by ultrasound.[246] In human ﬂuids, higher levels of van-
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comycin were needed to achieve a substantial reduction in adherent bacteria when compared to common bacterial mediums.
In order to obtain such levels of released vancomycin, polylactic
acid was coated to the porous PEEK puck to achieve both slow
and ultrasound-controlled release, which were enough to block
S. aureus adhesion to implants. The design was additionally revised to a one-/two-hole cylindrical PEEK depot that was able to
attach to a spinal rod for clinical applications.
Magnetic Manipulation Systems: Control of the movement of
micron-scale objects by the magnetic ﬁeld can generate suﬃcient
forces that may be used to prevent bacteria from attaching to
a surface and to remove established bioﬁlms on demand. For
example, Gu et al. demonstrated adjustable dynamic surface topographies composed of micropillars capable of beating at controlled frequency and magnitude in an electromagnetic ﬁeld (Figure 7E).[247] The optimized active topographies could reduce the
load of mature bioﬁlms of uropathogenic E. coli (UPEC), P. aeruginosa, and S. aureus by 3.7 logs. Additionally, the disengaged bacteria were sensitized to bactericidal antibiotics at a level similar to the planktonic cells. According to the same principle, they
prepared catheters with programmable surface topographies that
can keep clean for more than one month under the ﬂow of simulated urine solution, but the catheters without such topographies were occluded by UPEC bioﬁlms for less than 5 days. In
another study, Elbourne et al. showed that liquid metal droplets
made of gallium were magnetic responsive and capable of converting their shapes to develop sharp edges upon exposure to
a low-intensity rotating magnetic ﬁeld for 90 min, resulting in
physical destruction of bacterial cells and disruption of the compact EPS of bioﬁlms.[248]
Magnetic manipulation has also been used for the removal of
bioﬁlms in vivo. Yang et al. examined the eﬃcacy of superparamagnetic iron oxide nanoparticles and amoxicillin co-loaded chitosan/poly (acrylic acid) nanoparticles in treating Helicobacter pylori bioﬁlms.[249] They demonstrated that the nanoparticles may
inhibit the bioﬁlm and exert the bacteria-killing eﬀect against
H. pylori due to amoxicillin. Besides, the nanoparticles can stick
to the gastric mucosa due to chitosan’s mucoadhesive property
and quickly penetrate the mucosal membrane when exposed to a
magnetic ﬁeld, which can prolong the time drugs remain in the
gastry and decrease the dose and medication time, resulting in
eﬀective removal of H. pylori bioﬁlms. In a diﬀerent study, Quan
et al. used iron oxide nanoparticles (MIONPs) to interact with
staphylococcal pathogens through magnetic channel digging followed by gentamicin treatment to eradicate bioﬁlms.[250] It was
demonstrated that MIONPs can promote the eﬃcacy of gentamicin around 10 times against S. aureus Xen36 bioﬁlms in a mouse
subcutaneous infection model. Moreover, the highest CFU decrease was attributed to the MIONPs’ magnetic movement across
the bioﬁlms. At the same time, the isolated tissue around the infection location contained fewer inﬂammatory cells. Additionally,
magnetic materials have also been applied to assist in addressing the problem of implant-associated infections. Wang et al.
attempted to destruct bioﬁlms in implant-associated infections
using a magneto-based cooperative treatment.[251] It was shown
that CoFe2 O4 @MnFe2 O4 nanoparticles (MNPs) can break up
compact bioﬁlms due to the hyperthermia generated in an oscillating magnetic ﬁeld. Nitrosothiol-coated MNPs (MNP-SNOs)
were able to pass through the channels in dispersed bioﬁlms to
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eliminate bacteria because of the combinatorial eﬀect including
the released NO from nitrosothiols and the magnetic hyperthermia. Furthermore, MNP-SNOs can provoke macrophage-related
innate immunomodulation to avoid the recurrence of implantrelated infections. Meanwhile, the evident antimicrobial eﬀect of
this platform is further validated in a rat implant-related infection
model.
Catalytic Therapy: Various catalytic materials have been used
for the treatment of bioﬁlms via the generation of ROS. ROS
are critical for the immune system to combat microorganisms.
ROS can be produced by the NADPH oxidase in the innate immune cells.[252] ROS is capable of deactivating bacteria by destructing the proteins, DNA, and polysaccharides in an irreversible
way. Signiﬁcantly, ROS can break down the structure of mature bioﬁlms.[253] Among these catalytic materials, nanozyme
and polyzyme, which may promote the catalytic processes of natural enzymes and control the redox level of cells, in particular on
ROS, have been regarded as promising agents to kill bacteria and
eliminate bioﬁlm.[254] Huang et al. reported a catalytic polyzyme
consisting of lipophilic transition metal catalysts loaded with selfassembled polymer nanoparticles.[255] These nanoparticles provided a protective environment for the catalysts. The polyzyme
was demonstrated to be able to diﬀuse into bioﬁlms and get rid
of embedded bacteria via the bioorthogonal activation of a proantibiotic. In another study, Liang et al. investigated carbon dots
(CDs)@platinum nanoparticles (PtNPs) (CPP) nanoﬂare by integrating the CDs with PtNPs a peroxidase-mimicking nanozyme
for antibacterial/antibioﬁlm applications.[256] The CPP catalyzed
H2 O2 to generate ROS, exhibiting improved decontamination of
pathogens. Importantly, the CPP nanozyme demonstrated major bioﬁlm removal and wound healing eﬃcacy in vivo due to
endogenous H2 O2 in the acidic infection tissues. Such a strategy
may avoid antibiotic resistance to a great extent.
In recent years, many new catalytic materials have been applied to remove bioﬁlms in vivo. In a study, to address both drug
and mechanical resistance problems, Hwang et al. demonstrated
catalytic antimicrobial robots (CARs) capable of killing bacteria
and disrupting the EPS through catalytic activity and simultaneously removing the bioﬁlm from surfaces based on their magnetic actuation property (Figure 7F).[257] In their studies, two
small-scale robotic platforms with the incorporation of iron oxide nanoparticles serving as both magnetic actuator and enzymelike (e.g., peroxidase) catalysis were shown to destroy and remove
bioﬁlms in inaccessible, narrow spaces, or on surfaces. Robots
were controlled by the magnetic ﬁeld and moved along certain
directions to speciﬁcally wipe oﬀ dead bacteria and bioﬁlm remains. Their study demonstrated the capability of precisely targeting bioﬁlm eradication in unreachable sites or on various surfaces. In another study, Long et al. developed atomic-catalytic centered, hedgehog-like particles on a micron scale for combatting
MRSA through recapitulating the “capture and killing” feature
of macrophages.[258] The capture and killing eﬀect of synthesized
particles was attributed to the hedgehog topography and catalytic
production of ROS (e.g., •O2 − and HClO with Fe2 N6 O as catalytic centers). These macrophage mimicking particles showed a
low MIC against MRSA and enhanced wound healing in a rabbit skin wound infection model. It seems that the use of physical removal by magnetic actuation and ROS killing rendered by
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catalytic reactions may represent an eﬃcient combinatorial approach to eradicate bioﬁlms.
Electrical Stimulation: Electrical stimulation has been used
in several clinical scenarios including stimulation of nerves and
muscles, promotion of wound healing and bone regeneration,
and electrophoretic drug delivery.[259] Electrical stimulation has
also been studied for the treatment of bioﬁlms and it was ﬁrst
proved to be eﬀective in treating bioﬁlms in vitro. Kim et al.
showed the combination of electrical energy applied through alternating (AC), direct (DC), and superimposed (SP) potentials
and antibiotics to treat E. coli bioﬁlms (Figure 7G).[260] They
found that the energy rather than the type of electrical signal (e.g.,
AC, DC, or SP) mainly contributes to the antibioﬁlm eﬃcacy. The
results from this study shed new light on how electrical stimulation works and open opportunities to incorporate the bioelectric
eﬀect into the management of bioﬁlms in clinics.
Electrical stimulation has also been demonstrated to treat
contaminated medical devices and biomaterial-associated infections. Ercan et al. showed the reduction of S. aureus growth
on traditional titanium because of anodization and electrical
stimulation.[261] The results showed a dramatic decline in the S.
aureus bioﬁlm formation after culture for 2 days upon electrical
stimulation coupled with anodized nanotubular titanium, relative to non-anodized titanium without stimulation, which was
attributed to the ﬂuorine existing on the exterior of anodized
tubular titanium. In another study, Ehrensberger et al. examined the combination of electrical stimulation of titanium with
cathodic voltage and the use of antibiotics (e.g., vancomycin
and gentamicin) to avert bacteria attachment and periprosthetic
joint infection.[262] It was demonstrated that electrical stimulation
alone or in combination with antibiotics can fully get rid of MRSA
and P. aeruginosa bioﬁlms. Synthetic mesh is the most common
repair material used for reinforcement of ventral hernias, and infection of implanted mesh could lead to signiﬁcant morbidity for
patients. In view of this, Khan et al. examined the inﬂuence of
pulsed electric ﬁelds on P. aeruginosa bioﬁlms within polypropylene meshes (Figure 7H).[263] They studied how the electric ﬁeld
strength and the number of pulses aﬀected the removal of bacteria. Their data suggested that the enhanced treatment eﬃciency
was mainly attributed to the increased number of applied pulses.
Moreover, the bacterial killing rate was illustrated as a function
of the electrical ﬁeld which was able to ﬁt the statistical Weibull
model for 150 and 300 pulses.
Electrical stimulation could oﬀer an alternative treatment
method for bioﬁlms in skin wounds. Ashraﬁ et al. investigated
the eﬃcacy of electrical stimulation against bioﬁlms in bioﬁlmcontaining human skin wound models and simultaneously monitored the response of treatment in a non-invasive manner using
volatile organic compound (VOC) biomarkers.[264] It was shown
that electrical stimulation can signiﬁcantly reduce the viability,
metabolic activity, and biomass of MSSA and P. aeruginosa in
vitro and ex vivo relative to no treatment. It is worth noting that
the proﬁles of VOC produced by bacteria varied signiﬁcantly after
electrical stimulation which could be used as biomarkers for diagnosis and monitoring of wound infections responded to diﬀerent
treatments. The above-mentioned physical methods for bioﬁlm
eradication may allow the development of diﬀerent intervention
strategies to combat bioﬁlms. We further summarize the advan-

2203291 (20 of 36)

© 2022 The Authors. Advanced Science published by Wiley-VCH GmbH

www.advancedsciencenews.com

www.advancedscience.com

Table 1. The advantages and shortcomings of diﬀerent physical methods for eradicating bioﬁlms.
Physical methods

Advantages

Shortcomings

Refs.

Non-thermal (cold)
plasma

*Antimicrobials generated locally
*High level of oxidation/reactive species
renders resistance unlikely

*Accessibility of plasma
*Bioﬁlm EPS may protect cells deeper down
*Response to plasma is species-dependent
*Highly localized

[265]

Microbubbles

*Physical action reduces probability of
resistance *Readily combined with
irrigants and shear

*Accessibility
*Bioﬁlm can resist removal due to the
viscoelasticity
*Residual cells may remain

[266]

Photodynamic and/or
photothermal
therapy

*Antimicrobial activity can be controlled
locally
*Can be readily combined with surface
modiﬁcations

*Delivery to infected site and transport into
bioﬁlm
*Accessibility of light
*Bioﬁlm EPS may protect cells
* Cytotoxic eﬀects due to the generated heat

[265]

Ultrasound

*Readily projected through skin and soft
tissue
*Local delivery
*Physical action reduces probability of
resistance

*Limited targeting
*Inﬂuence of pressure waves on viscoelastic
bioﬁlms not well understood
*Local delivery limited to small and accessible
areas

[267]

Magnetic
manipulation
systems

*Avoiding the limited tissue penetration
*Physical targeting
*Eﬃciently penetrate bioﬁlm
*Bioﬁlm mechanical destruction

*Diﬃcult to target in vivo

[247,
268]

Catalytic therapy

*Use via the generation of reactive oxygen
species (ROS), deactivating bacteria by
destructing the proteins, DNA, and
polysaccharides
*Damage the EPS of bioﬁlms and weaken
the resistance of bacteria in bioﬁlms to
environmental stress

*Low therapeutic eﬃcacy without the addition
of H2 O2
*Lack of targeting ability to bacterial bioﬁlms

[257,
269]

Electrical stimulation

*Projected through induction or connected
wires
*On-demand antimicrobial generation
*Also promote wound healing

*Electrochemistry of body ﬂuids not well
understood
* Heat generation
*Delivery of electrical currents to deep tissue
*Cytotoxicity

[270]

tages and shortcomings of diﬀerent physical methods for eradicating bioﬁlms in Table 1.

4.2.2. Chemical Methods
Bacteriophages: Bacteriophages are one of the most numerous and diverse groups of viruses. Bacteriophages contaminate
bacteria, take control over their machinery, reproduce intracellularly, and are secreted by host cell lysis.[271] Being antibioﬁlm
therapeutics they are superior to antibiotics due to their deﬁned,
benign, self-reproducing, and self-restraint characteristics.[272]
Phage-borne depolymerases break down the bioﬁlm EPS the
physical hurdle for antibiotic diﬀusion and lead to substantial bioﬁlm destruction. Recently, bacteriophages have been frequently used in the treatment of bioﬁlms in vitro. Papadopoulou
et al. examined the eﬃcacy of bacteriophages in combating
Flavobacterium psychrophilum bioﬁlms in vitro in terms of inhibiting the formation and reducing the biomass of bioﬁlms.[273]
Their results indicated lytic bacteriophages could eﬀectively prevent the formation of F. psychrophilum bioﬁlms, and simulta-
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neously decrease the total mass of established bioﬁlms. Moreover, combining diﬀerent phages (e.g., Fpv-9 and Fpv-10) could
result in a signiﬁcant decrease in the total mass of formed F. psychrophilum bioﬁlms. In another study, Wroe et al. developed a
hydrogel that was able to load P. aeruginosa bacteriophage and deliver active phage to the infected area through injection.[274] The
bacteriophage-loaded hydrogels can eﬃciently eliminate the host
bacteria with diﬀerent phenotypes (e.g., planktonic and bioﬁlm)
exerting no eﬀects on the metabolism of human mesenchymal
stromal cells. The murine segmental bone defects with P. aeruginosa infection were treated with the bacteriophage-loaded hydrogels, resulting in 4.7 times CFU count decrease in the infected
area as opposed to hydrogels without incorporation of bacteriophage after implantation for 7 days.
Treating bioﬁlms with multiple types of antimicrobials with
diﬀerent acting mechanisms could be more eﬃcacious to combat
bioﬁlms composed of distinct bacterial strains when compared
to the treatment with a single antimicrobial agent.[275] Plota et al.
investigated the eﬃcacy of daptomycin and bacteriophage K in
killing S. aureus and S. epidermidis strains.[276] They noticed there
were no dramatic disparities between species. However, dapto-
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mycin showed higher eﬃcacy when using medium and high
concentrations of the drug. Bacteriophage K exhibited higher
killing eﬃcacy against more susceptible strains. When administering both daptomycin and bacteriophage K with high concentrations, they can obtain the best in vitro antibioﬁlm eﬀect. The
activity of bacteriophages has also been demonstrated against
clinically-relevant bacteria in vivo including antibiotic-resistant
strains. Their utility may be especially impactful in clinical settings where antibiotics fail. For example, Wang et al. assessed
the eﬃcacy of a bacteriophage ɸWL-3 together with antibiotics
in the treatment of an antibiotic-resistant E. coli bioﬁlm.[277] The
combinatorial treatment enhanced the antibioﬁlm eﬃcacy of antibiotics, in particular after sequential administrations, leading to
the reduction of 51-fold of the minimal bioﬁlm bactericidal concentration. Co-administration of ɸWL-3 and fosfomycin showed
better survivability relative to monotherapy in a Galleria mellonella
invertebrate E coli ATCC 25 922 infection model.
Nanomaterials: Nanomaterials can oﬀer antimicrobial properties and have been used as a carrier for antibiotics with
great stability and good biocompatibility. Nanomaterials with a
high surface-area-to-volume ratio have a large contact surface
with the bacterial cell membrane, exhibiting high therapeutic
eﬃcacy in treating bioﬁlms.[278] It is believed that the use of
nanomaterials for the development of antibioﬁlm approaches
is promising in combating bacterial infections and resistance.
Three steps are normally involved when nanomaterials interact
with bioﬁlms. The ﬁrst is to deliver nanomaterials to the surrounding area of bioﬁlms. The second is to adhere to the exterior
of bioﬁlms. The third is to inﬁltrate into bioﬁlms. The accomplishment of each step is controlled by numerous aspects such
as physicochemical properties of nanomaterials, bioﬁlm’s EPS,
and surroundings.[279]
Metal (Oxide) Nanoparticles: Metal nanoparticles, metal oxide nanoparticles, or their combinations have been used to
overcome limitations that occur in traditional antibiotics such
as hindrance in penetration and excretion from systems after
therapy.[289] Many studies have demonstrated metal nanoparticles are capable of providing antimicrobial or antibioﬁlm eﬀects.
The mechanisms involved in the bactericidal activity of metal
nanoparticles include the generation of ROS, release of ions,
and inﬂuence on the cell membrane of bacteria.[282] Among the
emerging metal nanomaterials, much attention has been paid
to silver nanoparticles (AgNPs) due to their potent antimicrobial activities and increasing applications in many nanomedicine
ﬁelds.[290] Gurunathan et al. investigated the eﬃcacy of silver
nanoparticles in conjunction with traditional antibiotics in treating diﬀerent human pathogenic bacteria and their corresponding
bioﬁlms.[291] Combining sublethal concentrations of antibiotics
and A. cobbe-mediated synthesized AgNPs showed a dramatic
increase in ROS production and cell death compared to AgNPs
or antibiotics only. When co-incubation of AgNPs, the antibacterial eﬃcacy of tested antibiotics, in particular ampicillin and
vancomycin, was greatly enhanced in combating Gram-negative
and Gram-positive bacteria. Recently, AgNPs were also combined
with other materials to exert or enhance their antibioﬁlm eﬀect.
Guo et al. developed silver nanocomposites by reducing AgNO3
in the presence of a carbohydrate polymer compatible with a living system and a cationic polymer capable of the destructing cell
membrane.[292] The nanocomposites were demonstrated to eﬀec-
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tively break up and get rid of the established bioﬁlms. Furthermore, the nanocomposites can eliminate the bioﬁlms established
on the silicone grafts implanted. Such nanocomposites could represent a novel approach to removing bioﬁlms on built-in medical
implants.
Besides metal NPs, NPs made of metal oxides, such as TiO2 ,
Fe3 O4 , ZnO, CuO, MgO, Al2 O3 , etc., and their nanocomposites
were also widely used as antibioﬁlm agents. Metal oxide NPs have
been demonstrated to interact with bacteria based on electrostatic
interactions, resulting in alterations of the bacterial cell wall, enzyme, or DNA pathways via generated ROS.[293] Recently, Naseer
et al. prepared CuO NPs from Cassia ﬁstula and Melia azedarach
leaf extracts using Cu(NO3 )2 .[294] The resultant NPs can inhibit
92.5% and 99.5% of K. pneumonia and H. pylori bioﬁlms, respectively, by disrupting bacterial cell shape and damaging DNA.
Similarly, metal oxide NPs could work together with other materials to exert greater antimicrobial activities. Banerjee et al.
showed zinc oxide NPs with pancreatin (PK) enzyme (ZnONPsPK) were able to better remove MRSA bioﬁlms than ZnO NPs or
PK alone,[295] indicating it was promising to use ZnONPs-PK for
treating infected swine dermis.
Use of diﬀerent combinations of metal nanomaterials could
have a synergistic antibioﬁlm eﬀect. For example, Jang et al. prepared Ag and Cu bimetallic NPs on a graphene oxide surface.[296]
The bimetallic NPs were able to eradicate the P. aeruginosa
bioﬁlm which grew in a microchannel. In addition, the local
administration of bimetallic NPs could result in fast and eﬃcient healing of a mouse bioﬁlm-infected skin wound model,
suggesting their potential applications in combating skin or
wound infections caused by antibiotic-resistant bacteria. In another study, Padilla-Cruz et al. developed Ag-Fe bimetallic NPs
by reduction from a chemical isolated from the leaves of Gardenia jasminoides.[297] The synthesized NPs showed a synergistic
killing eﬀect against multidrug-resistant bacteria due to the two
diﬀerent metal components. The potential antimicrobial mechanism for bimetallic NPs could be due to the oxidation of the
thiol side chain in cysteine existing in cell wall proteins by Fe+
causing changes in penetrability and oxidative stress induced by
the released Ag+ in the cytoplasm contributing to DNA damage
and membrane destruction. Other than antimicrobial activity, the
bimetallic nanoparticles were also responsive to an external magnetic ﬁeld because of the iron component.
Carbon-Based Nanomaterials: Carbon-based nanomaterials
(CNMs) are broadly applied in many areas including antibioﬁlm
agents because of their unique mechanical features, thermal persistence, and chemical stability.[298] The potential antimicrobial
mechanisms for CNMs could include physical and mechanical disruption, oxidative stress induction, photothermal reaction,
photocatalytic reaction, lipid extraction, bacterial metabolism inhibition, segregation by encasing, and cooperative eﬀects.[299]
CNMs have been applied to eradicate the formed bioﬁlm in
vitro. Li et al. designed a nanosystem based on carbon dots
stemming from the ashes of sintered L-lysine powder (CDLys )
and modiﬁed by a pH-responsive copolymer.[300] The nanostructures could quickly penetrate into the well-established S. aureus
bioﬁlm due to their hydrophilic corona and then break up into
two portions including -NH2 ended copolymer and CDLys due
to the responsiveness to the low-pH environment. The copolymer exhibited antimicrobial activity due to the coulomb interac-
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tion between negatively charged bacteria surfaces and the protonated -NH2 groups. The released CDLys were distributed across
the compact bioﬁlm, producing ROS to kill bacteria. Meanwhile, CNMs widely used as antibioﬁlm agents to eradicate the
bioﬁlm in vivo sometimes work cooperatively with other materials. Fan et al. demonstrated metal-organic-framework (MOF)derived 2D carbon nanosheets (2D-CNs) capable of eradicating bacteria topically.[301] The MOF-derived, ZnO-doped carbon
on graphene (ZnO@G) showed prolonged Zn2+ release, eﬃcient ions inﬁltration, and eﬀective photothermal killing synergistically enhancing the destruction of bacterial membranes
and intracellular substances. The 2D-CNs capable of eradicating
bioﬁlms were also able to eﬀectively treat skin wound infection
via photothermal eﬀect. In another study, Wang et al. developed
nitrogen-doped carbon quantum dots (N-CQDs) which were effective to kill MRSA without generating resistance, inhibit the
bioﬁlm formation, and remove established bioﬁlms.[302] It was
also shown that the administration with N-CQDs was able to
greatly decrease the bacteria CFU count in the infected tissue
and enhance wound closure in a mouse infectious skin wound
model.
Polymer-Based Nanoparticles: Polymeric NPs have many
unique features for antimicrobial agent delivery and have been
demonstrated as a powerful tool in combating bioﬁlms.[303] The
polymers including poly (lactic-co-glycolic acid) (PLGA), poly(𝜖caprolactone) (PCL), and chitosan (CS) are widely applied for
preparing NPs in bioﬁlm treatment. PLGA nanoparticle platforms lead the way for the development of multifunctional
drug delivery systems because of the easy surface modiﬁcation,
cell engulfment, and desired release proﬁles.[304] Notably, Iannitelli et al. encapsulated carvacrol in PLGA nanocapsules to
obtain a suitable drug delivery system that could treat bioﬁlmassociated infections.[305] In another study, Hasan et al. designed
a polyethyleneimine/diazeniumdiolate-doped PLGA NPs which
could attach to the EPS of MRSA bioﬁlm, leading to enhanced
antibioﬁlm activity.[306] The treatment with these NPs showed
complete bioﬁlm dispersal, reduction in bacterial burden, and acceleration in wound healing in a diabetic mouse MRSA bioﬁlminfected wound model. In addition, Deepika et al. reported PEGPLGA NPs co-loaded with natural and synthetic drugs (e.g., rutin
and benzamide) combating the bioﬁlms formed by MDR strains
of S. aureus and P. aeruginosa.[307] Such NPs can inhibit the adherence and attachment of bacteria to the substrate because of
their interference with bioﬁlm formation via a non-growth suppressive process.
CS is the biocompatible, biodegradable, and non-toxic Ndeacetylated derivative of chitin and has been broadly employed
in pharmaceutical and medical industries.[308] In addition, it has
been reported that chitosan and its derivatives show antibioﬁlm
activities.[309] CS NPs may serve as an ideal carrier for drug
delivery in the eradication of bioﬁlms.[310] Tan et al. demonstrated oxacillin and Deoxyribonuclease I (DNase) co-loaded CS
NPs have higher activity against S. aureus bioﬁlms in vitro than
oxacillin-loaded NPs and free drugs.[311] Such NPs could prohibit
the formation of bioﬁlms and disrupt the established bioﬁlms
eﬀectively via degrading eDNA and decreasing the number of
survived cells and the thickness of bioﬁlms. In another study,
Shrestha et al. developed CS NPs functionalized with rose-bengal
to enhance antibioﬁlm eﬀects, in which the antimicrobial activity
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was attributed to the adherence to the bacterial cell surface, penetration into the membrane, and lysis of the cells.[312] These NPs
were demonstrated to decrease the viability of Enterococcus faecalis and disrupt the bioﬁlm structure. In addition, Panwar et al.
prepared ferulic acid-loaded CS NPs for combating Candida albicans (C. albicans).[313] Their results revealed that drug-loaded
NPs disrupted the structure of C. albicans bioﬁlms and decreased
about 22.5% of metabolic activity of C. albicans relative to free
drugs and blank NPs.
Although PCL is not used so frequently as PLGA and CS, it
has been applied together with other materials (e.g., polymers
and lipids) for the delivery of antimicrobial agents. Cheow et al.
investigated levoﬂoxacin-loaded PCL NPs against E. coli bioﬁlms,
revealing their critical role in inhaled therapy against bioﬁlm infections, where the rapid release of levoﬂoxacin in the early stage
allows a high initial drug concentration and the subsequent prolonged release allows a high-sustained drug concentration to effectively prevent bioﬁlm growth and reduce the exacerbation.[314]
Kho et al. also explored respirable antibiotic-loaded PCL NPs
which are eﬀective in eradicating 99.9% of the E. coli bioﬁlm.[315]
In a diﬀerent study, Mir et al. prepared carvacrol-PCL NPs with
great potential against bioﬁlms composed of multidrug-resistant
pathogens.[316]
In addition to these three most common polymer-based NPs
mentioned above, there are also many studies on multi-block
and multi-functional polymeric NPs to eradicate bioﬁlms in
vivo. Li et al. demonstrated the self-assembly of block copolymer DA95B5, dextran-block-poly ((3-acrylamidopropyl) trimethylammonium chloride-co-butyl methacrylate) into NPs with a
non-fouling dextran shell and a cationic core which can effectively remove established bioﬁlms of diﬀerent multidrugresistant bacteria.[317] These NPs penetrated into bioﬁlms and adhered to bacteria without killing them, rather, they facilitated the
slow disperse of bacteria, probably due to the enhanced solubility of the bacteria-nanoparticle complex by the dextran shell (Figure 8A). The ﬁeld-emission scanning electron microscopy (FESEM) images showed that the cell number of gram-positive bacteria in the bioﬁlm decreased after administration with one dose
(128 μg mL−1 ) of DA95B5 (Figure 8B (I)). DA95B5 was used as
a solution in combination with a hydrogel dressing, exhibiting
better eﬃcacy (a 3.6-log reduction of MRSA) than vancomycin
in a murine excisional bioﬁlm-infected wound model (Figure 8B
(II)). CLSM was used to conﬁrm the diﬀusion of DA95B5 labeled with rhodamine into MRSA BAA40 bioﬁlms through a
time-lapse imaging. As indicated in Figure 8C, DA95B5 can diffuse into the MRSA BAA40 bioﬁlm in less than 5 min, likely
due to attractive interactions between charged molecules. Longer
time-lapse imaging shows a signiﬁcant drop in green ﬂuorescent
signals indicated by labeled MRSA BAA40 bacteria, suggesting
DA95B5 can disperse the MRSA BAA40 bioﬁlm. The interaction
of DA95B5 NPs with MRSA BAA40 bacteria was also investigated
by cryo-TEM (Figure 8D), showing the accumulation of DA95B5
near the surface of bacteria as NPs without breaking up the intact cell membrane. These observations show that DA95B5 NPs
can attach to the surface of Gram-positive bacteria without diﬀusing into the cytoplasm, indicating their non-bactericidal characteristics. Administration of DA95B5 NPs seems to be a new strategy for bioﬁlm eradication through the bacterial debridement on
nanoscale unlike traditional antibiotic therapy potentially devel-
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Figure 8. Block copolymer nanoparticles remove bioﬁlms via nanoscale
bacterial debridement. A) The possible mechanism of preformed bioﬁlm
removal by DA95B5 NPs. B) I): Representative SEM images of Grampositive bacteria. MRSA BAA40, VRE, and OG1RF bioﬁlms on pegs of the
MBEC bioﬁlm inoculator before and after DA95B5 treatment (with 128 μg
mL−1 ). II): Schematic illustrating DA95B5/vancomycin-soaked hydrogels
against MRSA BAA40 bioﬁlms in an established murine excision wound
model. III): Log CFU per wound from hydrogels alone and DA95B5-soaked
(2.5 mg kg−1 ) and vancomycin-soaked (2.5 mg kg−1 ) hydrogels. Each type
of hydrogel was applied 3 times at 4 h intervals before plating for CFU determination on agar plates. C) Penetration proﬁles of polymers at diﬀerent time points. Time-lapse 3D confocal images of MRSA BAA40 bioﬁlms
treated by DA95B5 at 128 μg mL−1 with incubation times of 0, 5, 10, 30,
60, and 120 min, showing the dispersal of bioﬁlms (Green is live bacterial
cells, Red is dead bacterial cells). D) Eﬀect of DA95B5 on the properties of
three Gram-positive strains. Cryo-TEM images showing I) MRSA BAA40
bacteria, II) DA95B5 NPs in PBS buﬀer, and III) the location of DA95B5
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oping drug resistance in bacteria and nonresponsive to multidrug resistant bacteria. Such a method should be as eﬀective
against resistant bacterial strains as against sensitive strains, indicating many potential applications.
Lipid-Based Nanoparticles: Lipid-based NPs are ideal carriers for drug delivery to bioﬁlms. Three of the most common
categories include solid lipid NPs (SLN), nanoemulsions, and
liposomes which have been reported for delivering antibacterial/antibioﬁlm agents. These carriers are critical for the elimination of bacteria.[318]
SLN has the potential to deliver antimicrobial agents for a long
duration, while reducing the negative eﬀects of drugs due to
the prevention of the environment from directly contacting the
drugs.[319] SLN shows good stability as antimicrobial agent delivery systems in vivo and is superior to traditional drug formulations. Singh et al. developed SLNs of cefuroxime axetil against
S. aureus bioﬁlm, showing twofold higher antibioﬁlm activity
than free drug in vitro.[320] In a diﬀerent study, Anjum et al.
prepared anacardic acid-loaded SLNs, and then coated with chitosan and DNase using a layer-by-layer approach due to electrostatic interactions.[321] The design rationale for coating DNase
and chitosan was based on the hypothesis that DNase can disrupt the bioﬁlm by degrading the e-DNA and chitosan can enhance the adherence to bioﬁlms due to its positive charge. The
synthesized SLNs showed lower MBIC and minimum bioﬁlm
eradication concentration against S. aureus bioﬁlms when compared with control, demonstrating the superior design of anacardic acid formulations. In another study, Akhtari et al. fabricated
rifampin and cis-2-decenoic acid co-loaded SLNs with higher antibioﬁlm eﬃcacy in vitro than free drugs in particular in the
bioﬁlm-forming phase.[322]
Nanoemulsions with good kinetic stability greatly improve the
solubility of antimicrobial agents. Notably, the utilization of these
nanoemulsions could promote antimicrobial eﬃcacy.[323] Song
et al. investigated the antibacterial and antibioﬁlm eﬃcacy of designed chlorhexidine acetate nanoemulsions.[324] The nanoemulsions had higher eﬃcacy in combating MRSA in comparison to
its water solution. It also showed higher eﬃcacy in the prevention
of bioﬁlm formation and eradication of the bioﬁlm. In another
study, Quatrin et al. successfully produced nanoemulsions that
contain Eucalyptus globulus oil.[325] The nanoemulsions with a
size of around 76 nm and a zeta potential of −9.42 mV showed antimicrobial and antibioﬁlm activities against three tested species
of Candida but without exhibiting antimicrobial activity against
P. aeruginosa likely because of the low oil content. Moreover,
Fang et al. examined the antimicrobial and antibioﬁlm eﬃcacy
of cetylpyridinium chloride-incorporated nanoemulsions against
MRSA.[326] They found the smaller the droplet size, the higher the
antibioﬁlm eﬀect of nanoemulsions. The nanoemulsions with
small size exhibited excellent antibioﬁlm activity, resulting in a
tenfold CFU decrease relative to the control.
Liposomes are composed of phospholipid bilayers which are
compatible vesicles and stand for one of the most studied organic

NPs in the MRSA BAA40 bacteria. The arrows denote NPs coated onto
the bacterial surface. Reproduced with permission.[317] Copyright 2018,
American Chemical Society.
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Figure 9. Liposomes containing cinnamon oil against MRSA bioﬁlms. A) Schematic illustrating liposomes containing cinnamon oil with anti-bioﬁlm
activity against MRSA bioﬁlms. B) SEM of MRSA bioﬁlms before and after the treatment of liposomes containing cinnamon oil. C) CLSM images of
MRSA bioﬁlms before and after the treatment of liposomes containing cinnamon oil. Reproduced with permission.[331] Copyright 2016, Taylor & Francis
Group.

NPs for antimicrobial agent delivery.[327] Antimicrobial agents
loaded liposomes are able to penetrate bioﬁlms, exhibiting high
eﬃcacy in treating bioﬁlms composed of many types of bacterial species.[328] Many researchers focus on using liposomes to
deliver or enhance antibioﬁlm agents. For example, Giordani
et al. incorporated a biosurfactant extracted from Lactobacillus
gasseri BC9 into liposomes and then demonstrated their capability in inhibiting the bioﬁlm establishment and removing MRSA
bioﬁlms.[329] In particular, biosurfactant-incorporated liposomes
exhibited better eﬃcacy than free biosurfactants in preventing
MRSA bioﬁlm formation. To improve the bioavailability, dissolution, and cellular uptake, Bhatia et al. encapsulated berberine
and curcumin in liposomes and demonstrated co-encapsulated
liposomes can more eﬀectively hamper the growth of MRSA and
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inhibited the establishment of bioﬁlms when compared to free
drugs.[330] Additionally, Cui et al. loaded cinnamon oil, a natural
and safe spice, in liposomes to increase the stability and examined their antibioﬁlm eﬃcacy against MRSA on diﬀerent substrates (e.g., gauze, stainless steel, fabrics, and nylon membrane)
by quantiﬁcation of CFU count (Figure 9A).[331] The changes
of MRSA bioﬁlms in morphology were examined by SEM and
CLSM after treatment with liposomes containing cinnamon oil.
Figure 9B shows an SEM image, indicating the bioﬁlms attached
to the nylon membrane without treatment appeared to be congested spheres. After treatment with liposomes containing cinnamon oil, an evident reduction in terms of the thickness and
size of bioﬁlms was observed. The CLSM images showed much
lower ﬂuorescent intensities for the bioﬁlms after administration
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Table 2. The advantages and shortcomings of the four most common types of nanomaterials for combating bioﬁlms.
Nanomaterials

Advantages

Shortcomings

Refs.

Metal (Oxide) Nanoparticles

* Controllable long-term stability
*Long-lasting drug release
*High surface-to-volume ratio
*Abundantly available and has the ability to
adapt to extreme conditions.

*Potential toxicity of long-lasting exposure
*Low speciﬁcity to the target tissues

[280–282]

Carbon-based Nanomaterials

*Excellent physicochemical properties and
structural characteristics
*Environmentally benign nature
*Good biocompatibility

*High production costs
*Limited in penetrate and target eradicating bioﬁlms.

[283, 284]

Polymer-based Nanoparticles

*As drug carriers that deliver the antibioﬁlm
molecules
*Flexible structures and predictable kinetics have
aided the nanoparticle penetration
*Stability against high temperature, enzymatic or
microbial degradations

*Biosafety, cytotoxicity, and hemolytic activity,
especially those with positively charged surfaces

[285, 286]

Lipid-based Nanoparticles

*Could incorporate with other antibioﬁlm drugs
*Could encapsulate hydrophilic and lipophilic
compounds in the same structure
*Targeting ability
*Cytotoxicity reduction of the antimicrobials as
compared with their free form

*Low retention time can imply higher doses over time

[287, 288]

with cinnamon oil-loaded liposomes when compared to the control samples (Figure 9C). It seems that 1.0 mg mL−1 of cinnamon
oil-loaded liposomes could destruct the MRSA bioﬁlm. All these
studies demonstrated that liposome formulations could enhance
the stability of various antimicrobial drugs and prolong their action time. To better compare these four most common types of
nanomaterials used for combating bioﬁlms, we list their advantages and drawbacks in Table 2.
Antimicrobial Peptides: The use of AMPs as a substitute for
antibiotics has sparked great interest in the past twenty years,
and more recently AMPs have been applied for combating microbial bioﬁlms.[332] AMPs (over 3000 in the updated AMP database
https://www.aps.unmc.edu) are broad and can fold into a variety
of structures, ranging from linear to cyclic scaﬀolds.[333] Many
linear peptides become amphipathic helix, which is ideal to permeabilize bacterial membranes. Such a property makes them
uniquely eﬀective in the rapid killing of multidrug-resistant bacteria. Hence, they are eﬀective against both dormant and growing cells, irrespective of the cells’ metabolic state.[334] The positive charge of AMPs promotes preferential interaction with negatively charged bacterial surfaces rather than host cells.[335] However, several disadvantages of such linear peptides limited their
clinical applications, such as high instability because of the fast
degradation and lysis by proteases.[336] However, some cyclic peptides (e.g., vancomycin and daptomycin) have already been used
clinically.[337] Currently, many scientists are committed to developing synthetic/engineered AMPs to overcome the disadvantages of linear AMPs and improving the production of new cyclic
peptides to make them more eﬃcient or available in the ﬁeld of
bioﬁlm elimination.
Cathelicidin-derived peptides exert potent antimicrobial and
antibioﬁlm activity against many species of multi-drug resistance pathogens. For example, Pompilio et al. examined the antibioﬁlm eﬃcacy of multiple peptides stemming from catheli-

Adv. Sci. 2022, 9, 2203291

cidin in the treatment of S. aureus, P. aeruginosa, and S. maltophilia strains that were obtained from patients with CF.[338]
It was found that established bioﬁlms were dramatically inﬂuenced by sheep myeloid AMPs-27/28/29 in their bactericidal concentrations. This study suggests the possibility of using cathelicidin-derived peptides as therapeutics for the management of CF lung disease. Blower et al. reported the cathelicidin
peptides (e.g., LL-37, NA-CATH, and SMAP-29) were eﬀective
to inhibit the Burkholderia thailandensis bioﬁlm formation.[339]
They also demonstrated that preformed bioﬁlms could be dispersed by LL-37 and its D-enantiomer D-LL-37. Mishra et al. discovered that the major AMP (GF-17) of LL-37 and its engineered
peptide (17BIPHE2) were more eﬀective than their parent peptide in disrupting preformed bioﬁlms of MRSA.[340] In the case
of clinical P. aeruginosa, a combination of 17BIPHE2 with conventional antibiotics was more eﬀective in disrupting preformed
bioﬁlms.[128] In addition, LL-37 engineered peptides with stability
to proteases prevented bioﬁlm growth on a catheter implanted in
murine.[341,342] It appears that longer LL-37 peptides have a certain advantage in bioﬁlm disruption.[343]
Studies have reported AMPs and the modiﬁcation of their
sequence to achieve novel antibioﬁlm therapeutics with enhanced eﬃcacy and more stability against proteolytic lysis.
For example, Thankappan et al. fabricated a helical cationic
peptide KABT-AMP with the sequence GIWKKWIKKWLKKLLKKLWKKG, showing wide-spectrum antimicrobial activity to
kill diﬀerent bacterial and fungal strains.[344] The peptide was
also eﬀective to treat the Candida tropicalis (a clinical isolate)
bioﬁlm. Cardoso et al. reported an Escherichia coli-derived AMP
(EcDBS1R5) created by pattern recognition and subsequent sequence optimization.[345] Two to 32 μm EcDBS1R5 was able to
hamper the growth of diﬀerent strains including Gram-positive
and Gram-negative, susceptible, and resistant bacteria. Moreover,
EcDBS1R5 at a concentration of 16 μm was eﬀective to treat es-
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tablished P. aeruginosa bioﬁlms by reducing the survival rate of
bioﬁlm-forming bacteria. The antibacterial and antibioﬁlm eﬃcacy of EcDBS1R5 was further demonstrated by a 2-log reduction of P. aeruginosa CFU count in a scariﬁcation skin infection mouse model. Zapotoczna et al. synthesized an AMP which
could be used as a catheter lock solution for combating S. aureus
bioﬁlm infections.[346] The results revealed that the D-Bac8c2, 5Leu
variant was very eﬃcient in eliminating S. aureus bioﬁlms on
the central venous catheter in rats. It is worth mentioning that
Narayana et al. designed two potent amphipathic short peptides
based on database guidance and structure theory (Figure 10).[347]
These two peptides had the same amino acid sequence exhibiting two diﬀerent amphipathic structures including a typical horizontal helix (horine) and a new vertical spiral structure (verine)
upon binding to membranes. The solid-state 15N NMR data indicated the horizontal and vertical orientations of peptides on
membranes (Figure 10A). Multi-drug resistant bacteria covering
most ESKAPE pathogens were used to examine the potency of
horine and verine. These two peptides were eﬀective in treating
gram-positive pathogens including VRE and MRSA. The bacterial damage was characterized by SEM. The S. aureus surface
was smooth without treatment. Contrarily, the membrane blebs
were observed after horine treatment. The K. pneumoniae surface was completely destructed after incubation with verine (Figure 10B). S. aureus USA300 LAC and persisters were rapidly destroyed when treated with peptides at double concentrations of
MIC (Figure 10C (I), (II)). Their eﬃcacy against bioﬁlms was further assessed that are extremely hard to remove using traditional
antibiotics. Verine was found to hamper the adherence of K. pneumoniae (Figure 10C (III)). Besides, these peptides also showed activity against the established bioﬁlms. Horine showed eﬃcacy in
the treatment of S. aureus USA300 bioﬁlms in a concentrationdependent manner (Figure 10C (IV), green), but nafcillin was
ineﬀective (Figure 10C (IV), gray). Similarly, verine destructed
the established K. pneumoniae bioﬁlms (Figure 10C (VII), gold).
In contrast, doripenem was not eﬀective against bioﬁlms in the
same experiment (Figure 10C (VII), gray). These two peptides
can kill the pathogens in bioﬁlms as shown by CLSM images.
Bacteria were living in green without treatment (Figure 10C (V),
(VIII)), while bacteria were dead in red after treatment (Figure 10C (VI), (IX)). This work represents a step forward to acquiring new antibiotics as majority of AMPs developed so far are
mainly promising for topical treatment of infections and the peptides developed in this work greatly enhanced the survival rate of
mice with sepsis and eliminated the infections associated with
major organs in the body after one shot without exerting any evident negative eﬀects.
Combined Chemical and Physical Approach: Antimicrobial Microneedles: The microneedle patch is a device consisting of a
membrane and an array of microscale needles on the surface
which was initially invented for transdermal drug delivery. Contrasting to injections using traditional hypodermic needles, microneedle patches are normally considered as a low-cost, localized, and minimally invasive drug administration approach.[348]
Microneedles can assist drugs to penetrate the major diﬀusion skin barrier stratum corneum or directly deliver drugs to
the microcapillary in the dermis by simply varying the geometric dimensions of microneedles or tailoring the force applied to the patch. This technology has been broadly investi-
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gated since its ﬁrst appearance in 1998 for many applications
including vaccination, anti-diabetic therapies, anti-obesity therapies, anti-inﬂammatory therapies, local anesthesia, contraception, and anti-tumor therapies.[349] Based on a similar principle,
microneedles could readily penetrate the major diﬀusion barrier
EPS of bioﬁlms for delivery of various antimicrobial agents.
To overcome the shortcomings (e.g., poor penetration, oﬀtarget side eﬀects, and induction of antibiotic resistance) of current treatment approaches, Xu et al. showed a microneedle patch
for eﬀective treatment of bioﬁlms through enhancing the penetration into the bioﬁlm and precisely delivering antibiotics to
speciﬁc locations.[350] The patches consisted of dissolvable microneedle arrays where the needle tips were incorporated with
chloramphenicol-loaded, gelatinase-responsive gelatin nanoparticles. The hypotheses were that the microneedles can physically
pass through the EPS and after the rapid dissolution of the microneedles, the gelatin NPs can release encapsulated chloramphenicol within the bioﬁlm matrix upon exposure to gelatinase
produced by resident microbe. The microneedle system appeared
to be more eﬀective than free drugs in terms of the treatment
of Vibrio vulniﬁcus bioﬁlms. However, this work was limited to
the use of microneedle patches for treating bioﬁlms in vitro. In
another study, Woodhouse et al. generated a ﬂexible microneedle array patch that was able to simultaneously deliver oxygen
and antimicrobial agents.[351] The microneedle patches consisted
of needle arrays made of polyvinylpyrrolidone and calcium peroxide and a ﬂexible polyethylene terephthalate substrate. Such
patches can raise the oxygen contents from 8 to 12 ppm in the
ﬁrst 2 h after administration meanwhile showing high eﬃcacy
in treating one-week-old bioﬁlms normally seen in skin wounds.
This study further demonstrated the penetration of the microneedle arrays and eﬀective management of bioﬁlms in an ex vivo
porcine wound infection model. Similarly, Permana et al. demonstrated a dissolvable microneedle array patch with the incorporation of bacterial responsive doxycycline-loaded NPs for promoting bioﬁlm penetration and delivering doxycycline to the infected
areas.[352] Such a patch was able to reduce the bacterial bioburdens by about 99.99% in an ex vivo porcine skin bioﬁlm model
after being applied for 48 h.
It is known that sometimes bioﬁlms regrow within days after treatment. In light of this, Su et al. reported a novel Janustype dressing consisting of molecularly engineered AMPs-loaded
dissolvable microneedles arrays and electrospun nanoﬁber membranes serving as a substrate.[353] It was believed that microneedle arrays can physically pass through bioﬁlms and release AMPs
within bioﬁlms and electrospun nanoﬁber membranes can release peptides to the outside of bioﬁlms. The released peptides from both needles and nanoﬁbers could cause bioﬁlm removal initially. In comparison, the sustained-release peptides
from nanoﬁber membranes may be able to prevent the recurrence of bioﬁlms. The dressing, comprising of nanoﬁber substrate and water-soluble microneedle arrays, allowed precise delivery of AMPs to both interior and exterior of the bioﬁlms (Figure 11A). Notably, this dressing can eliminate MRSA bioﬁlms
formed in ex vivo human skin wounds (Figure 11B,C) and type
II diabetic mice wounds (Figure 11D,E) after administration day
by day without performing debridement. In addition, the dressing could get rid of the bioﬁlms consisting of P. aeruginosa and
MRSA binary strains established in ex vivo human skin wounds

2203291 (27 of 36)

© 2022 The Authors. Advanced Science published by Wiley-VCH GmbH

www.advancedsciencenews.com

www.advancedscience.com

Figure 10. Two distinct amphipathic peptide antibiotics with antibioﬁlm eﬃcacy. A) N-labeled leucine in horine (K) and verine-L (L) indicates an H-N
vector (red) parallel to membrane surface, which allows to position the 3D structure of horine (left) and verine-L (right) on the lipid bilayer so that the
H-N vector (in ball-and-stick) is approximately parallel to the bacterial membranes. B) SEM of S. aureus and K. pneumoniae before and after the AMP
treatment. C) in vitro antibioﬁlm eﬃcacy of horine (green) and verine (gold). I): Horine and verine (2 × MIC) killed the exponential phase S. aureus
USA300 LAC in 120 min. II): The two peptides (2 × MIC) also killed nafcillin-induced persisters of S. aureus. III): Verine, but not doripenem, inhibited
the attachment of K. pneumoniae E406-17 in a dose-dependent manner. IV): Horine disrupted the S. aureus bioﬁlms established in 48 h. In the confocal
images, live bacteria in the untreated control are in V) green and VI) dead bacteria treated by 16 μm of horine are in red. VII): Verine was eﬀective in
disrupting the Klebsiella bioﬁlms established in 48 h. In the confocal images, live K. pneumoniae are in green, and dead K. pneumoniae are in IX) red.
Reproduced with permission.[347] Copyright 2020, National Academy of Science.
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Figure 11. Microneedle-based dressings for eradication of bioﬁlms on skin wounds. A) Schematic illustrating Janus-type antimicrobial dressings consisting of molecularly engineered peptide-loaded electrospun nanoﬁber membranes and microneedle arrays for the treatment of bioﬁlms in chronic
wounds. B) Photograph showing the bioﬁlm treatment by Janus-type antimicrobial dressings in an ex vivo bioﬁlm-containing human skin wound model.
C) The antibioﬁlm eﬃcacy test of Janus-type dressings in an ex vivo human skin wound model. The dressings were changed three times every 24 h. D)
Live/dead staining for the tissue collected from wounds after 24 h of MRSA inoculation and subsequent 24 h of 2% mupirocin treatment, indicating
the bioﬁlm formation in type II diabetic mice wounds. E) Antibioﬁlm eﬃcacy of Janus-type antimicrobial dressings in vivo. The dressings were changed
three times every 24 h. F) Antibioﬁlm eﬃcacy of Janus-type dressings against P. aeruginosa/MRSA blend bioﬁlms in an ex vivo human skin wound model.
The dressings were changed three times every 24 h. PCL-F127: PCL-F127 nanoﬁbers. PCLF127/W379: W379 peptide-loaded PCL-F127 nanoﬁbers. PCLF127/W379+aqueous W379: W379 peptide-loaded PCL-F127 nanoﬁbers + free W379 peptides. PCL-F127/W379+PVP/W379 MN: Janus-type dressing
composed of W379 peptide-loaded PCL-F127 nanoﬁber membrane and W379 peptide-loaded microneedle arrays. Without treatment: no treatment for
the wounds. Reproduced with permission.[353] Copyright 2020, American Chemical Society.

as well (Figure 11F). However, the engineered AMPs are considered new chemical entities during the regulatory approval process. Because of the attrition rate of the current drug discovery
model, high cost, and time-consuming, it is reasonable to reformulate the current antimicrobial agents used in clinics for the
eﬀective management of bioﬁlms. Thus, Su et al. attempted to incorporate multiple antimicrobial agents (e.g., AgNO3 , Ga(NO3 )3 ,
and vancomycin) that target bacteria with diﬀerent modes of
action into a biphasic dressing similar to the above-described
comprising of water-soluble microneedle arrays and electrospun
nanoﬁber membranes for eﬀective treatment of bioﬁlms.[354] The
dressings can remove both MRSA and MRSA/P. aeruginosa blend
bioﬁlms formed in ex vivo human skin wounds without using
debridement. These studies were primarily focused on the treatment of bioﬁlms in wounds. Microneedle arrays could attach to
3D scaﬀolds to generate functional wound dressings capable of
eﬀectively delivering multiple distinct molecules such as antimicrobial agents, immunomodulating compounds, and growth factors for the elimination of bioﬁlms in wounds and promotion
of healing. Taken together, these recent developments add ﬂexibility to antibioﬁlm treatments depending on the nature of the
resistant pathogens. A combination of AMPs with existing antimicrobial agents, especially via the co-delivery device, holds a
great promise for eradicating diﬃcult-to-treat bioﬁlms contain-
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ing pathogens that cannot be killed by traditional antibiotics
alone.

5. Future Directions
Despite great strides have been made because of the discovery of
many antibioﬁlm agents and strategies, the bioﬁlm-related infections remain to be a public health problem. In order to develop
more eﬀective strategies for combating bioﬁlms, it is necessary
to better understand the biology of bioﬁlms which will eventually beneﬁt the identiﬁcation of new targets for the eradication
of bioﬁlms. Current in vitro bioﬁlm models are mainly established by culturing bacteria on diﬀerent substrates. Because of
the convenience, we anticipate the continued use of microplates
in bioﬁlm research. In rich media, the formation of bioﬁlms is
time-dependent and indicated by a constant level of biomass.[128]
It allows the analysis of bioﬁlms by diﬀerent staining methods
(e.g., crystal violet and XTT) for additional insight.[129] The results obtained in such a static model can be similar to those obtained in a ﬂuidic bioﬁlm model.[340] Additional knowledge can
be obtained by developing new bioﬁlm models. For example, a
better in vitro bioﬁlm model could be developed by printing bacteria and hydrogels which will be capable of mimicking native
bioﬁlms.[355–359]
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In order to develop more eﬀective approaches for managing
bioﬁlms, future studies should aim to identify new targets for disrupting bioﬁlms. Furthermore, the advances in genetic tools and
resources (e.g., genome-wide transposon insertion libraries) may
provide a high-throughput screening platform to ﬁnd out new
targets among the non-essential genes.[360] In combination with
new technologies (e.g., CRISPR interference (CRISPRi) knockdown), it may be possible to better understand the molecular
mechanisms of bioﬁlm-related functions (e.g., identifying genes
linked with the release of eDNA).[361] The discovered new targets
will be important to assist in developing new antibioﬁlm agents
and strategies, including a combined use with inhibitors with existing antibiotics.
In addition, other than interactions between bacteria within
bioﬁlms, the bacteria within bioﬁlms use electrical signaling to
recruit distant motile cells in a species-independent manner to
expand bioﬁlms.[362] Molecules or methods to disrupt the electrical signaling within bioﬁlms could be used to inhibit their
expansion and formation. Combinatorial therapies are promising for bioﬁlm treatment. Use of combinations of antimicrobial
agents with distinct acting mechanisms normally provides the
best synergistic eﬀect in both bacterial killing and the reduction
of drug resistance development.[363] The antibiotic-resistant bacteria could be sensitive to combinatory therapies, while monotherapies may not be eﬀective.[364] This approach could be vital
to reuse many antibiotics otherwise useless because of multidrug
resistance although the molecular mechanism is not fully understood.
Although many delivery systems have been developed for combating bioﬁlms, more eﬀorts should be devoted to the development of on-demand antimicrobial drug delivery systems by integrating soft electronic devices with biosensors.[365,366] In this
way, it may be possible to avoid the unnecessary delivery or
overdose of antibiotics and eventually reduce the chance to develop drug resistance. In addition, more studies should be carried
out to discover more reliable biomarkers which can be used to
sense infection at an early stage. Additionally, triggering bioﬁlmdisruptive activity in response to pathogenic micro-environments
(e.g., acidic pH, hypoxia, temperature, and pathogen-derived
metabolites) and targeting bacteria speciﬁcally (e.g., bacterial exotoxins, outer membrane proteins, d-amino acids of cell membrane, and competitive displacement) could be other interesting
directions.[367–369] The ultimate goal may concentrate on the development of doable and aﬀordable dosage forms and collaborations with industrial partners to achieve the highest potency and
safety with long-lasting therapeutic eﬀects and minimal cytotoxicity for use in clinics.
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[70] I. Strużycka, Pol. J. Microbiol. 2014, 63, 127.
[71] W. H. Bowen, R. A. Burne, H. Wu, H. Koo, Trends Microbiol. 2018,
26, 229.
[72] I. Kleinberg, Crit. Rev. Oral Biol. Med. 2002, 13, 108.
[73] W. Krzyściak, A. Jurczak, D. Kościelniak, B. Bystrowska, A. Skalniak,
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